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Abstract
ELECTRONIC CIGARETTE USER PLASMA NICOTINE CONCENTRATION AND PUFF
TOPOGRAPHY: INFLUENCE OF LIQUID NICOTINE CONCENTRATION AND USER
EXPERIENCE
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Major Director: Thomas Eissenberg, Ph.D.
Professor of Psychology
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Electronic cigarettes (ECIGs) aerosolize an often nicotine-containing solution for user
inhalation. ECIG nicotine delivery may depend on liquid nicotine concentration and user puffing
behavior (topography). This study examined the relationship among liquid nicotine
concentration, puff topography, and plasma nicotine concentration. Thirty-three ECIGexperienced and 31 ECIG-naïve individuals completed four laboratory sessions that differed by
ECIG liquid nicotine concentration (0, 8, 18, or 36 mg/ml). A 3.3 volt “eGo” ECIG battery
attached to a 1.5 Ohm dual coil “cartomizer” filled with 1 ml of 70% propylene glycol/30%
vegetable glycerin nicotine liquid was used in two ECIG-bouts (10 puffs; 30 s IPI). Plasma
nicotine concentration, puff topography, and HR were evaluated. Some ECIG/liquid
combinations can deliver physiologically active doses of nicotine to users, and nicotine delivery
depends on liquid nicotine concentration and user puffing behavior. Liquid contents, device
characteristics, and user behavior should be considered when regulating ECIGs.
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Electronic Cigarette User Plasma Nicotine Concentration and Puff Topography: Influence of
Liquid Nicotine Concentration and User Experience
Tobacco cigarette smoking is related to a myriad of negative health consequences
including cancer, cardiovascular disease, and stroke (Mathers & Loncar, 2006). Despite overall
declines in consumption, tobacco use remains a pervasive public health threat. Approximately
16.8 % of U.S. adults and 9.3 % of adolescents continue to smoke combustible tobacco cigarettes
(Jamal, et al., 2015; Singh et al., 2016). Because smoking remains the leading preventable cause
of death in the U.S. (i.e., approximately 480,000 individuals annually; USDHHS, 2014),
reducing the use of tobacco cigarettes is an important public health goal (Agaku et al., 2014).
However, nicotine, a constituent of tobacco products, is dependence-producing and nicotine
dependence in cigarette smokers makes smoking cessation difficult (e.g., Benowitz, 2008;
Stratton, Shetty, Wallace & Bondurant, 2001). Perhaps in response to the health threat of
combustible cigarettes, several alternative tobacco products have been introduced to the U.S. and
global markets. Typically, these products are advertised to reduce smokers’ exposure to harmful
tobacco constituents, such as tobacco specific nitrosamines, polycyclic aromatic hydrocarbons,
and/or carbon monoxide (CO) but often are intended to deliver nicotine. Electronic cigarettes
(ECIGs) are one of the newest and most prevalent types of alternative tobacco products, but their
potential to reduce tobacco-related harm is unknown. Furthermore, the health implications of
long term ECIG use are unclear. Below is a description of ECIG device and liquid
characteristics, prevalence and use patterns, the regulation of ECIGs, the acute effects of ECIGs
(i.e., nicotine delivery) and implications for nicotine-dependent and -naïve individuals.
ECIGs are a class of products that, until recently, were unregulated in the U.S. However,
in May of 2016 the Food and Drug Administration (FDA) announced that it will extend its
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authority to regulate tobacco products to include ECIGs (Deeming Tobacco Products To Be
Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking
Prevention and Tobacco Control Act, 2016). ECIGs heat a liquid solution, often containing
nicotine, and produce an inhalable aerosol. ECIGs typically contain a power source (e.g.,
battery), a heating element (called an “atomizer”), and store a liquid solution (composed of
solvents, flavors, and sometimes nicotine) in a reservoir. While power source, heating element,
and liquid solution are common features of most ECIGs, a wide variety of ECIG models exist
with considerable differences in device characteristics, such as the storage and nicotine
concentration of the liquid solution, the method for heater activation, and the electrical power
flowing through the heater (Breland, Spindle, Weaver, & Eissenberg, 2014).
Electronic Cigarette Models
ECIG models vary considerably, and therefore are best described as a class of products
(Breland et al., 2014). Over 466 different ECIG brands are available on the market with numbers
continuing to increase (Zhu, Sun, Bonnevie, Cummins, Gamst, Yin, and Lee, 2014). Some of the
most popular ECIG models, referred to as a “cig-alikes,” resemble traditional tobacco cigarettes
(see Figure 1; Breland et al., 2016). These models often contain a light-emitting-diode that glows
at the non-mouth end when the heating element is activated, typically as a result of user
inhalation. Cig-alike models store a liquid solution in a cartridge referred to as a “cartomizer”
that is attached to or contains the internal heating element (see Figure 1). Cartridges can be
depleted of liquid after some period of use and therefore require the user to replace or refill them.
Other cig-alike models require disposal of the ECIG in its entirety (Breland et al., 2014; Etter,
2012). Recently released devices operate under similar principles but do not resemble a cigarette
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(e.g., “JUUL”, see Figure 1; Giroud, de Cesare, Berthet, Varlet, Concha-Lozano, & Favrat.,
2015).
Other ECIG models do not resemble cigarettes and contain non-disposable, rechargeable
batteries and either contain ECIG liquid in storage reservoirs (called “tanks”) or in pre-filled
cartridges (see Figure 1; Etter, 2012). Users may refill cartridges or “tanks” as needed by
purchasing refill solution. By manually activating a button on the mouth-end of the device, the
user can activate the heating element and ready the device for aerosol production during
inhalation (Breland et al., 2014; Etter, 2012). These ECIG models allow for users to vary many
characteristics including: the power (measured in watts), that can be controlled by altering the
voltage (V) of the power supply and/or the resistance (Ohms or Ω) of the heating element (Etter,
2012). Manipulating product characteristics can alter the toxicant yield of the aerosol that
emerges from the mouth end of the device (Kosmider, Sobczak, Knysak, Goniewicz, 2014; Talih
et al., 2015).
For example, altering voltage and resistance (i.e., power) combinations in ECIG models
can influence the yield of nicotine and other toxicants produced from ECIGs (e.g., Kosmider, et
al., 2014; Talih et al., 2015). One analytical laboratory study demonstrated how device
characteristics, puffing behavior and ECIG liquid composition may alter toxicant yields (Talih et
al., 2015). In this study, aerosols were generated using machinery to simulate distinct puffing
profiles of various types of users based on their puff duration in seconds (s) and puff velocity in
milliliters per second (ml/s): for example, tobacco cigarette smoker puffs were 2 s duration at 33
ml/s puff velocity, slow average ECIG user puffs were 4 s at 17 ml/s, and fast extreme ECIG
user puffs were 8 s at 33 ml/s. Additionally, voltage (3.3 or 5.2 V, which converts to 3.0 or 7.5
W using a 3.6 Ohm heating coil) and the nicotine concentration of the ECIG liquid (18 or 36
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mg/ml) were varied. Results indicated that nicotine yield from 15 puffs varied across conditions
(Talih et al., 2015). Overall, nicotine yield generated from ECIG-experienced individuals puffing
profiles resulted in higher nicotine yield compared to tobacco cigarette smoker profiles. For
example, when device and liquid nicotine concentration were held constant, aerosol nicotine
yield after 15 puffs differed: mean (SD) for tobacco cigarette smokers puffing profiles was 0.11
mg (0.02) while for ECIG user puffing profiles nicotine yield ranged from 0.29 mg (0.08) to 0.72
mg (0.10) depending on the puffing profile (Talih et al., 2015). Nicotine yield may not
necessarily represent the amount of nicotine delivered to the user’s blood (i.e., nicotine delivery),
but these results suggest that the longer puffs observed in ECIG-experienced individuals (relative
to -naïve cigarette smokers; Hua, Yip, & Talbot, 2013) cause the device to emit more nicotine
with each puff. Also, when voltage was varied and puffing behavior, resistance, and liquid
nicotine concentration were held constant, aerosol nicotine yield after 15 puffs differed: mean
(SD) at 3.3 V was 0.3 mg (0.01) while for 5.2 V was 1.2 mg (0.3; Talih et al., 2015). The many
potential voltage and resistance (i.e., power) combinations in ECIG models highlight the need for
evaluation and regulation of ECIG device characteristics.
ECIG Liquid Solutions
Similar to ECIG device characteristics, ECIG liquid solutions vary widely. These
solutions are often referred to as “e-liquid” and typically are composed of solvents like propylene
glycol (PG) and/or vegetable glycerin (VG) and often, but not always, flavorants and nicotine
(Etter, 2012). When PG and/or VG are heated and aerosolized, they act, alone or in combination,
as the vehicle for any nicotine and/or flavorants that are present (Etter, 2012).
ECIG nicotine yield can be influenced by liquid nicotine concentration or the PG/VG
ratio of the liquid (Kosmider et al., 2014; Talih et al., 2015). However, few empirical
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investigations have been conducted to determine how liquid nicotine concentration and the
PG/VG solvent ratio influence nicotine yield during acute ECIG use. In one study, user
experience, battery output, and ECIG liquid composition was analyzed to determine how these
factors affect the nicotine yield of an ECIG (Kosmider et al., 2014). In this study PG/VG ratio
and battery voltage were manipulated while other variables were held constant. ECIG aerosol
generated and was later analyzed for nicotine yield. Nicotine yield was related directly to PG/VG
ratio: higher PG levels resulted in higher nicotine yield but only when using a device under 4.8
volts. To date, this is the only study in which the influence of PG/VG ratio on nicotine yield has
been investigated.
Another factor that may influence nicotine yield is the liquid nicotine concentration of
ECIG liquid. In one study, user puffing behavior, ECIG liquid composition, and certain ECIG
design features were manipulated in order to examine how these factors influence nicotine yield
(Talih et al., 2015). ECIG aerosol was generated using machinery to simulate distinct puffing
profiles of various types of users and liquid nicotine concentration was varied using either 8.5 or
15.7 mg/ml. Increases in liquid nicotine concentration were found to be associated with increases
in nicotine yield. Specifically, when all other factors were held constant and liquid nicotine
concentration was increased from 8.5 mg/ml to 15.7 mg/ml, mean (SD) nicotine yield increased
from 3.2 (0.3) mg to 4.7 (1.0) mg after 15 puffs. Collectively, results from these studies are
consistent with the notion that at least some aspects of ECIG liquid composition – PG/VG ratio
and nicotine concentration – can influence ECIG nicotine yield.
Of particular concern is the inconsistency between actual and advertised nicotine
concentrations observed in ECIG liquids (Bahl et al., 2012; Trehy et al., 2011). For example,
some ECIG liquids advertised as containing no nicotine (0 mg/ml) contain trace levels of

6

nicotine (Trehy et al., 2011). In addition, the liquid nicotine concentration stored in the
cartridges of six popular United Kingdom ECIG brands was analyzed to explore labeling
inconsistencies (Goniewicz, Hajek, McRobbie, 2012) and a variation in liquid nicotine
concentration of up to 12% was observed. Indeed, in one clinical study involving ECIGexperienced participants, two participants brought into the laboratory liquid they used regularly
that was labeled “12 mg/ml” but subsequent analysis revealed that the liquid contained no
measurable nicotine (Spindle, Breland, Karaoghlanian, Shihadeh, & Eissenberg, 2014). Overall,
the liquids that participants brought to the laboratory in this study highlight the variety of liquid
flavors, nicotine concentrations, PG/VG ratios of these products, as well as the complexity of
understanding the effects of ECIG use (see Table 1; Spindle et al., 2015).
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Figure 1. From the left, JUUL ECIG with disposable pod, “cig-alike” ECIG models that store
ECIG liquid in a cartridge (i.e. “cartomizer”), pre-filled, or fillable cartridge, refillable and
reusable “tank” system, rechargeable batteries, and modifiable or “variable voltage” batteries
(Adapted from Breland et al., 2016).
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Table 1.
Variability in ECIG Liquid Nicotine Concentration and PG/VG Ratio
Participant

Nicotine Concentration
mg/ml

Solvents
PG/VG ratio

Liquid Flavor

1
2
3
4
5
6
7
8
9
10
11
12
13

24
24
24
18
24
24
24
24
24
24
18
12
18

100/0
50/50
Not available
70/30
50/50
30/70
80/20
Not available
30/70
50/50
30/70
30/70
60/40

No flavor
Gargamel’s Curse
Torque 56
Watermelon
Peach
Gold Rush
DK Blend
Menthol
Persian Winter
Vanilla Dr. Pepper
Gold Rush
Aztec
Carolina Crush

Data are from 13 individuals who participated in a study in which they used their own ECIG
device and liquid. The table includes participant liquid nicotine concentrations, flavors, and
propylene glycol to vegetable glycerin ratio (as indicated by product labeling; table adapted from
Spindle et al., 2015).
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ECIG Use Patterns and Reasons for Use
ECIGs were patented in China in 2003 (Lik, 2003) and introduced into the U.S. market in
2007 (Regan, Promoff, Dube, & Arrazola, 2013). Since their introduction ECIGs have become
common in U.S. and global markets. ECIG popularity in the U.S. market can be illustrated by
reports of their revenue growth, with sales having tripled from $273 to $636 million between
2012 and 2013 (Giovenco, Hammond, Corey, Ambrose, & Delnevo, 2015).
Adult ECIG Use. U.S. surveys have demonstrated steady increases in ECIG use among
adults (King, Patel, Nguyen, & Dube, 2014). “Ever use” of ECIGs in U.S. adults has increased
from 1.8 % in 2010 to 13 % in 2013 (McMillen, Gottlieb, Shaefer, Winickoff, and Klein, 2015).
Overall, current tobacco cigarette smokers have higher ECIG use rates compared to other ECIG
using groups (i.e., never smokers and former smokers; King et al., 2013). A survey among 5,939
current and former smokers in Canada, the U.S., the United Kingdom, and Australia found that
8% of current and former smokers had tried ECIGs between 2010 and 2011 (Adkison, West,
Beard, Michie, Shahab, & McNeill, 2013). Heavy cigarette smokers had the highest ECIG use
rates, while long term quitters had the lowest use rates (Adkison et al., 2013). A more recent
national survey of 36,697 U.S. adults (≥18 years) found that 12.6% of adults reported having
“ever used” ECIGs, 3.7% reported current ECIG use (defined as using ECIGs on some days) and
1.1% reported daily ECIG use (Delnevo, Giovenco, Steinberg, Villanti, Pearson, Niaura, &
Abrams, 2016). A more detailed examination of the data revealed that 12.7 % of daily cigarette
smokers and 11.5 % of “some-day” cigarette smokers reported current ECIG use. Among
individuals who quit cigarette smoking recently (i.e., quit 1 year ago or less), 5.0% were current
ECIG users relative to the 0.3 % of never smokers who were current ECIG users (Delnevo et al.,
2016). Importantly, among adults, the reason reported most commonly for using ECIG use is to
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reduce consumption of conventional tobacco cigarettes or to quit smoking altogether (Berg,
Haardoerfer, Escoffery, Zheng, & Kegler, 2015; Richardson, Pearson, Xiao, Stalgaitis, &
Vallone, 2014).
Adolescent ECIG Use. Perhaps most concerning are the ECIG use rates among youth
and adolescents, especially those who have not initiated tobacco cigarette use or nicotine use.
The National Youth Tobacco Survey (NYTS), a cross-sectional school based survey
administered to U.S. middle and high school students, reported that, as of 2015, ECIGs were the
most popular tobacco product among middle and high school students (Singh et al., 2015).
Reported use rates were 5.3% for middle school and 16% for high school students (Singh et al.,
2015). This same survey found statistically significant increases in current (i.e., past 30-day use)
ECIG use among high school students. For example, from 2011 to 2015, current ECIG use
increased from 1.5% to 16% in high school students (Singh et al., 2015). Also in 2015, of those
middle and high school students who reported current tobacco use, 3 million reported also using
ECIGs. Use rates have also increased among adolescents who reported never having used
tobacco cigarettes. In 2011, 79,000 never-smoking adolescents reported ECIG use while 263,000
reported ECIG use in 2013 (Bunnell et al., 2014). Taken together, ECIG use is increasing among
various age groups and among tobacco/nicotine experienced individuals as well as those who are
tobacco/nicotine naïve.
The variability in product design/ECIG liquid features (Breland et al., 2014) paired with
increasing popularity among adults and youth in the U.S. and internationally suggests a need for
systematic evaluation of the effects of ECIGs. These systematic empirical investigations will be
vital for effective ECIG regulation.
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Regulation: Tobacco Control Act
The Family Smoking Prevention and Tobacco Control Act (or Tobacco Control Act;
TCA) gave the FDA the power to regulate the manufacture, distribution and marketing of certain
tobacco products (Family Smoking Prevention and Tobacco Control Act, 2009). Cigarettes,
cigarette tobacco, roll-your-own tobacco, and smokeless tobacco were covered immediately by
FDA's tobacco product authorities. The statute also provided FDA with the authority to issue
regulations for other tobacco products not covered initially by the statute. FDA defines tobacco
products as “any product made or derived from tobacco that is intended for human consumption,
including any component, part or accessory of the tobacco product” (Deeming Tobacco Products
To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family
Smoking Prevention and Tobacco Control Act, 2016). In May of 2016, under the “deeming”
statute, the FDA announced that their regulatory authority would be extended to include ECIGs,
which were unregulated in the U.S. for several years (Deeming Tobacco Products To Be Subject
to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention
and Tobacco Control Act, 2016). ECIGs meet the statutory definition of a tobacco product as
they often contain nicotine derived from tobacco. The FDA’s regulatory power over ECIGs will
include general controls (e.g., registration of products, listing ingredients, and provisions against
adulteration and misbranding) and premarket review (Deeming Tobacco Products to Be Subject
to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention
and Tobacco Control Act, 2016).
Now that FDA has asserted this new regulatory authority over ECIGs, science must help
inform regulation by examining systematically what these products do, what ingredients they
contain, and the extent to which they will have a positive or negative public health impact. The
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information generated by tobacco scientists may guide regulatory agencies regarding the
labeling, marketing, and distribution of various products. While a variety of methods and
techniques are needed, and many are being applied to ECIGs, human laboratory studies already
are informing regulatory agencies about the acute effects of ECIGs. Some of the acute ECIG
effects that have been studied include pulmonary function, nicotine delivery, abstinence
symptom suppression, and cognitive effects (Breland et al., 2014). The review below focuses on
ECIG nicotine delivery, the factors that influence nicotine delivery, and the implications of
ECIG nicotine delivery on various populations who use these products (i.e., nicotine-dependent
and nicotine-naïve individuals).
What Do ECIGs Do: Nicotine Delivery
ECIGs are marketed to tobacco users as being capable of delivering nicotine to the user.
Nicotine delivery can be characterized as the amount of nicotine detected in the user’s body and
is most often measured in blood plasma (i.e., plasma nicotine concentration, in ng/ml) following
use. To date, various clinical laboratory studies have included measurement of plasma nicotine
concentration following ECIG use, typically with within-subject study designs (e.g., Dawkins &
Corcoran, 2014; Farsalinos et al., 2014; Vansickel & Eissenberg, 2013) and sometimes including
a tobacco cigarette control condition (e.g., Vansickel et al., 2010).
When assessing ECIG-associated nicotine delivery, many studies have used
methodologies that are drawn from clinical laboratory methods developed to study the effects
and use behavior associated with tobacco cigarettes. For example, some ECIG studies include ad
libitum ECIG use bouts that allow the user to puff on an ECIG as often as they like during a set
period of time (e.g., Farsalinos et al., 2014; Vansickel et al., 2013), as has been done for tobacco
cigarettes (Breland, 2005; Blank, 2009; Gust & Pickens, 1982; Herning et al., 1983; Rose & Behm,
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2003). Other ECIG studies include a combination of both ad libitum use and “directed ECIG use

bouts” (or directed use bouts only): during directed use bouts, participants are instructed to take a
specified number of puffs over the course of a fixed time period in order standardize use
behavior (Vansickel et al., 2010; Vansickel & Eissenberg, 2013; Farsalinos et al., 2015), as has
been done for tobacco cigarettes and other combustible tobacco products (Blank, Nasim, Hart, &
Eissenberg, 2011; Griffiths, Henningfield, & Bigelow, 1982)
Standardizing participant puffing behavior has become commonplace in the evaluation of
a variety of novel tobacco products (Breland, Buchhalter, Evans, & Eissenberg, 2002; Blank,
Nasim, Hart, & Eissenberg, 2011). This standardization is useful to the extent that it allows for
comparisons across products and the parameters used reflect actual use behavior by a population
of interest (e.g., cigarette smokers). Most often the puffing behavior that is standardized includes
puff count (i.e., the number of puffs taken) and inter-puff interval (IPI). IPI is often defined as
the time between the onset of one puff and the onset of a subsequent puff (as seen in Vansickel et
al., 2010, Farsalinos et al., 2014; Spindle et al., 2015). Data from cigarette smokers support the
idea that a 10-puff bout is typical during the consumption of a single tobacco cigarette. For
example, a six-condition, within-subject design study intended to compare three different
techniques for measure puffing behavior (desktop, portable, or video method) involved 30
cigarette smokers using two different types of cigarettes (own brand versus ultra-light) ad libitum
(Blank, Disharoon, & Eissenberg, 2009). Mean (SD) puff number during this ad libitum use was
9.7 puffs (3.3) with the desktop topography measurement system, 9.4 puffs (3.0) with the
portable measurement system, and 9.2 puffs (3.2) with the video method recording (Blank et al.,
2009). This study also included measurement of IPI in these same participants, with results
suggesting that 18 s IPI was the norm. These results support the use of a 10-puff directed bout,
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but do not support a 30 s IPI (See also Kleykamp, Jennings, Sams, Weaver, Eissenberg, 2008 for
similar support for 10 puffs but not for 30 s IPI). However, in both studies, participants were
overnight abstinent, which may have influenced user puff topography.
In one study involving 36 non-abstinent smokers, participants completed four, 5-day
conditions that differed by product, and one product was the participants’ own brand of tobacco
cigarette. Laboratory measurement of ad libitum puff topography was conducted on days 1 and
5 of each condition. In the own brand condition, mean (SD) puff number was 10 puffs (3.1) on
day 1 and 10 puffs (2.7) on day 5 (Breland, 2005), providing strong support for notion that 10
puffs is typical for a tobacco cigarette smoker smoking a single cigarette. Moreover, mean (SD)
IPI on day 1 was 30.7 s (12.8) and on day 5 was 30.5 s (9.6; Breland 2005). This study, that
included tobacco cigarette smokers who had not been abstaining from cigarettes prior to puff
topography measurement, may be more representative of naturalistic puffing behavior, and
results are consistent with the notion that a 30 s IPI is typical of a tobacco cigarette smoker.
Several ECIG studies now include 10-puff, 30 s IPI directed use bouts when measuring
plasma nicotine concentration following acute ECIG use. One study illustrated this methodology
when examining the nicotine delivery of two “cig-alike” models in 32 ECIG-naïve cigarette
smokers (Vansickel et al., 2010). In this four condition, within-subject study, participants used
either their own brand cigarette, an “NPRO” (18 mg/ml nicotine cartomizer) ECIG, a “Hydro”
(16 mg/ml nicotine cartomizer) ECIG, or a sham (unlit cigarette). During each session,
participants completed a 5 minute 10-puff use bout (with 30 s IPI) with the product assigned for
that session. Mean peak changes in plasma nicotine concentration were 1.4 ng/ml for the
“NPRO” and 0.5 ng/ml for the “Hydro” (Vansickel et al., 2010). However, these same users
obtained mean peak changes of 18 ng/ml following tobacco cigarette use under the same
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conditions. These results demonstrate the value in using 10-puff directed ECIG use bouts as they
allow for standardization and comparison in nicotine delivery between tobacco cigarette and
ECIG use.
Some studies indicate that ECIGs are capable of delivering nicotine, particularly when
used by individuals who have previous experience using these products. For example, one
within-subject study examined differences in nicotine delivery using a “cig-alike” model (“V2”
ECIG with a cartomizer, device wattage not reported) and a “tank” based device (“EVIC”, 9
watts) in 23 ECIG-experienced users. Both devices were filled with the same solution
(“Flavourart Maxblend,” 18 mg/ml nicotine concentration, 35/65 PG/VG ratio) and participants
completed one 5-minute, 10-puff ECIG use bout (with 30 s IPI) and plasma nicotine
concentration was measured immediately following the bout. Mean (SEM) plasma nicotine
concentrations rose from 2.8 (0.4) ng/ml to 4.9 (0.5) following 10 puffs from the “cig-alike” V2
ECIG compared to an increase from 2.5 (0.3) to 7.0 (0.6) ng/ml using the “EVIC”. The “cigalike” model delivered significantly less nicotine to the user compared to the tank-based ECIG
model following the 10-puff directed bout (Farsalinos et al., 2014). However, neither product
delivered nicotine at levels comparable to those typically associated with combustible cigarettes
(i.e., approximately 18 ng/ml after 10 puffs with a 30 s IPI; Vansickel et al., 2010), even in the
hands of ECIG-experienced users.
The ability for ECIG-experienced individuals to obtain nicotine from ECIGs was also
demonstrated in a study that examined nicotine delivery in eight ECIG-experienced individuals
using their own devices (all of which were tank or cartridge-based models). This study included
one 10-puff directed ECIG use bout (30 s IPI) and 60 minutes of ad libitum use (Vansickel &
Eissenberg, 2013). After the directed 10-puff ECIG-use bout, average plasma nicotine
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concentration (SEM) was 10.3 ng /ml (2) while their mean plasma concentration (SEM)
observed after 60 minutes of ad lib use was 16.3 ng/ml (4.5; Vansickel & Eissenberg, 2013).
These plasma nicotine values approach those typically observed in tobacco cigarette smokers
after a 10 puff bout (i.e., approximately18 ng/ml; Vansickel et al., 2010).
Only one study to date has compared the nicotine delivery profile of ECIG-experienced
and -naïve individuals while holding device features and liquid nicotine concentration constant
(Farsalinos et al., 2015). In this study, 24 ECIG-experienced and 23 -naïve participants took 10
puffs (30 s IPI) from an “EVIC” ECIG (9 watts) attached to an “EVOD” atomizer, or “tank”
filled with 2 ml of liquid (“Flavourart Maxblend,” 18 mg/ml nicotine concentration, 35/65
PG/VG ratio; Farsalinos et al., 2015). Following 10 puffs from the ECIG mean (SEM) plasma
nicotine concentrations rose from 2.1 (0.3) ng/ml to 7.9 (0.9) ng/ml in ECIG-experienced
individuals and from 1.6 (0.3) ng/ml to 4.3 (0.7) ng/ml in ECIG-naïve tobacco cigarette smokers
(Farsalinos et al., 2015). While there was a statistically significant between-group difference,
these plasma nicotine concentrations do not approach the nicotine delivery profile of a
combustible tobacco cigarette following 10 puffs (i.e., approximately18 ng/ml; Vansickel et al.,
2010).
Finally, only one study has compared the nicotine delivery profile of ECIG-experienced
individuals while varying liquid nicotine concentration and holding all other device features
constant (Dawkins, Kimber, Feyerabend & Cocoran, 2016). In this study, 11 ECIG-experienced
men were asked to use an ‘eVic supreme’ (3.9 V; 8.5 watts) ECIG attached to a ‘Nautilus
Aspire’ tank filled with either low (6 mg/ml) or high (24 mg/ml) liquid nicotine in two separate
study sessions. Following 60 minutes of ad libitum use of the study product, mean (SEM) plasma
nicotine concentration boost (i.e., change in plasma nicotine concentration calculated by
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subtracting baseline nicotine concentration from post ECIG use plasma nicotine concentration)
in the 6 mg/ml condition was 8.6 (7.5) ng/ml after 10 minutes of use, 16.9 (11.7) ng/ml after 30
minutes, and 22.0 (16.2) ng/ml after 60 minutes. In the 24 mg/ml condition plasma nicotine
concentration boost from the baseline was 33.8 (34.9) ng/ml after 10 minutes, 35.5 (28.3) ng/ml
after 30 minutes, and 43.6 (34.8) ng/ml after 60 minutes. This study demonstrates larger nicotine
boost when using the 24 rather than the 6 mg/ml liquid nicotine concentration. However, the 60
minute ad lib puffing protocol makes understanding whether a relationship between liquid and
plasma nicotine concentration exists difficult to glean from these results as differences in plasma
nicotine concentration may also be a function of differences in puff topography (i.e., puff
number, duration or volume) across different liquid nicotine concentrations. Thus, a more
controlled puffing regimen with limited puff number may have been more indicative of a direct
relationship between liquid and plasma nicotine concentration.
Collectively, studies on ECIG use have shown that not all ECIG models are capable of
delivering the same amount of nicotine to the user while other models may be capable of
delivering nicotine profiles comparable to that of tobacco cigarette use, at least under ad libitum
use conditions (Vansickel et al., 2013). Some studies have demonstrated that ECIGs do not
deliver nicotine to inexperienced individuals (Vansickel et al., 2010). Conversely, some ECIG
devices deliver nicotine to experienced individuals but only under certain conditions (Breland et
al., 2014; Dawkins & Corcoran, 2014; Vansickel & Eissenberg, 2013; Farsalinos et al., 2014).
Finally, only one study has demonstrated that ECIG-experienced individuals obtain higher
plasma nicotine concentrations compared to -naïve individuals even when holding device, liquid
nicotine concentration, and puffing constant (Farsalinos et al., 2015).
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The aforementioned studies illustrate inconsistencies in nicotine delivery following ECIG
use as a result of device features and user experience. The variability in nicotine delivery
between ECIG-experienced and -naïve individuals may be explained by differences in smoking
behavior (i.e., puff topography). For example, relative to ECIG-naïve smokers, ECIGexperienced individuals may modify their puffing behavior when using an ECIG such that their
puffing differs from the puffing behavior when using a tobacco cigarette (Breland et al., 2014).
Measurement of puff topography (as described below) likely is an important component of
studies designed to inform ECIG regulation by providing data relevant to understanding the
effects of nicotine-containing products in users.
Puff Topography
The evaluation of puff topography has been used to understand the smoking behavior of
tobacco cigarette users and is now being used to characterize the puffing profile of ECIG users.
Puff topography is the measurement of puffing behaviors such as puff number, volume, duration,
and IPI, and is often examined using mouthpiece-based computerized devices (Blank, Disharoon,
& Eissenberg, 2009). In tobacco cigarette users, puffing behavior has helped explain the
relationship between nicotine intake and exposure to other harmful tobacco constituents
following conventional tobacco cigarette use (Gust & Pickens, 1982; Herning, Jones, Benowitz,
& Mines, 1983). For example, puff topography helped explain why “low-yield” cigarettes did
not actually reduce smoking-related harm (e.g., Herning, Jones, Bachman, & Mines, 1981). One
study examined the puff topography of 24 abstinent cigarette smokers using either “low,”
“medium,” or “full flavor” cigarettes while holding tar, and carbon monoxide yields constant
(Herning et al., 1981). Participants using “low-yield” cigarettes took larger and longer puffs
which resulted in CO delivery comparable to that of a “full flavor” cigarette, indicating that these
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“low-yield” cigarettes would do little to reduce smoking-related harm. These results demonstrate
that measuring puff topography is critical when examining inhalable tobacco products.
Measurement of Puff Topography. The measurement of topography has been a
valuable tool in understanding the maintenance of tobacco use and nicotine delivery of various
tobacco products. The most commonly used instrument for measuring puff topography requires
the placement of cigarettes into a specialized mouthpiece that is capable of detecting flowinduced pressure changes that occur as a result of user inhalation. A pressure transducer senses
pressure changes and converts them to flow rate (puff velocity) using previously calibrated
software. The software then calculates puff duration, volume, and IPI using these converted flow
rate measurements (Blank, 2008). One such mouthpiece-based topography device known as the
Clinical Research Support System (CReSS) has been validated in laboratory studies for
measuring topography in cigarette smokers (Blank et al., 2009; Buchhalter & Eissenberg, 2000).
Puff topography may be useful in explaining some of the variability in ECIG-associated nicotine
exposure.
Puff Topography of ECIGs. To date, one published study has examined ECIG
topography using a computerized measurement system specially designed to measure ECIG use
(Spindle et al., 2014). The mouthpiece-based device used in this study (designed at the American
University of Beirut) operated similarly to devices used to measure cigarette smoker’s puff
topography (e.g., CReSS) but was sensitive enough to capture accurately low flow rate puffs
typically associated with ECIG use (Behar et al., 2015). Prior to this study, there was no
evidence to suggest whether or not mouthpiece based topography systems would interfere with
ECIG-associated nicotine delivery or subjective effects. Plasma nicotine concentration and
subjective effects were measured in 13 ECIG-experienced users (with their preferred device and
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liquid) during 2 sessions that differed only by the presence of the topography device (and its
mouthpiece attachment). Sessions included a 5 minute 10-puff directed bout and a 90 minute ad
libitum session. This study demonstrated that ECIG-experienced individuals are capable of
obtaining nicotine when using their own devices. Specifically, mean (SEM) plasma nicotine
concentration immediately following a 10-puff directed ECIG use bout 19.2 ng/ml (2.3) was
significantly greater relative to baseline 2.4 ng/ml (0.2) and 10 minutes after ECIG use 10.2
ng/ml (1.1; Spindle et al., 2015). Additionally, this study further demonstrated the ability for
ECIG-experienced users to obtain cigarette-like plasma nicotine concentrations (i.e., 18 ng/ml;
Vansickel et al., 2010). Finally, this study demonstrated that the ECIG topography recording
device did not influence nicotine delivery or most subjective responses. Mean (SEM) plasma
nicotine concentration immediately following a 10-puff directed ECIG use bout was 19.9 ng/ml
(1.0) in the no topography condition and 21.3 ng/ml (3.1) with the topography device present
(Spindle, personal communication).
This study also demonstrated differences in puffing behavior between ECIG-experienced
users and tobacco cigarette smokers by comparing puffing results (i.e., volume, duration, and
flow rate) from 13 ECIG users to 123 tobacco cigarette smokers from a previous study
completed in the same laboratory under similar conditions (Kleylamp, 2008). The results
demonstrated that ECIG users take puffs that are, on average, larger and longer than cigarette
smokers, and also have much slower flow rate-puffs. Mean (SD) of ECIG users volume were
101.4 ml (50) compared to 51.3 ml (19.2) in tobacco cigarette users. Similarly, ECIG users took
longer puffs lasting 4.2 s (1.1) compared to tobacco cigarette smokers who took 1.4 s (0.4) puffs
(Spindle et al., 2015). Finally, ECIG users flow rate was 24.2 ml/s (10.7) compared to cigarette
smokers flow rate of 38 ml/s (9.7).
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Similarly, other studies have used video observation methods to compare the puffing
behavior of ECIG users to that of tobacco cigarette smokers. Some of these studies suggest that
ECIG-experienced individuals take longer puffs (approximately 4 s, on average) while ECIGnaïve smokers take shorter puffs (approximately 2 s, on average; Hua et al., 2013; Farsalinos et
al., 2013). The shorter puffs demonstrated by ECIG-naïve smokers are comparable to puff
durations observed in cigarette smokers using their preferred brand of cigarettes (Farsalinos et
al., 2013). These studies demonstrate that when using an ECIG for the first time, ECIG-naïve
smokers may need to modify their puffing behavior in a manner that resembles the puffing
behavior of an ECIG-experienced individual.
To date, one study has demonstrated that ECIG-naïve cigarette smokers appear to adjust
their average puff duration and flow rate during the first week of a two week ECIG trial (Lee,
Gawron, & Goniewicz, 2015). In this study, 20 tobacco cigarette smokers used a M201 type
(Mild, Poland) ECIG containing 11.0 mg of nicotine as determined in a previous study
(Goniewicz et al., 2013). Participants were asked to use the provided ECIG for two weeks as a
substitute for their tobacco cigarettes. Baseline topography was measured in the laboratory prior
to the 2 week ECIG trial and also 7 and 14 days after baseline. At each visit, 8-hour abstinent
participants puffed on an ECIG ad libitum while puff topography was measured using a
CressMicro monitor. During baseline, ECIG use, mean (SEM) puff duration of smokers was 2.2
s (0.1), after one week puff duration was 3.1 s (0.3), and after two weeks puff duration was 2.9 s
(0.2; Lee et al., 2015). Mean puff duration after one week of ECIG use increased significantly
from baseline. Puff flow rate also changed from baseline with participants having a flow rate
decrease from 30.6 ml/s (2.3) to 25.1 (1.8) ml/s after one week, down to 24.8 ml/s (1.9) after
week two. These data demonstrate that smokers may modify their puffing behavior after
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switching from tobacco cigarettes to ECIGs. Overall, users took longer and slower puffs after
one week of ECIG use and this change in puffing behavior is believed to be an adaptation to the
factors that influence ECIG nicotine emissions (Lee et al., 2015). These studies highlight the
importance of measuring puff topography in ECIG users in order to measure how variability in
puffing behavior may alter nicotine delivery.
In summary, ECIG nicotine delivery varies considerably. The ability of ECIGs to deliver
nicotine may depend on the variability in device and liquid characteristics such as liquid nicotine
concentration. Also, relative to ECIG-experienced,-naïve individuals may be less effective at
obtaining nicotine and this may be reflective of differences in puff topography. The nicotine
delivery profile of ECIGs needs to be examined further given the potential public health
implications of ECIGs delivering varying amounts of nicotine to different populations over a
prolonged period of time.
Described below are the potential implications of ECIGs delivering little to no nicotine,
cigarette-like levels of nicotine, or exceeding the nicotine delivery profile of a tobacco cigarette.
The various populations that may be impacted by ECIG nicotine delivery include nicotine-naïve
and currently nicotine-dependent individuals (i.e., adult or adolescent cigarette smokers).
ECIGs Nicotine Delivery: Implications for Various Populations
Combustible tobacco use remains the leading cause of preventable death in the U.S. and
reducing tobacco related morbidity and mortality is an important public health goal (USDHHS,
2014). ECIG proponents argue that ECIGs may serve to reduce tobacco related death and disease
as they do not operate via combustion and may expose their users to less harmful toxicants (e.g.,
tobacco specific nitrosamines, polycyclic aromatic hydrocarbons, and carbon monoxide [CO])
but purportedly continue to deliver nicotine (Etter, 2013; Glynn, 2014; Grana, Glantz, & Ling,

23

2011; McRobbie, Bullen, & Hajek, 2012). Other ECIG proponents surmise that ECIG use may
be one approach to helping smokers quit or reduce tobacco cigarette consumption (Abrams,
2014; Etter, 2013). However, the assertion that ECIGs may be a less harmful substitute for
tobacco cigarettes remains controversial (Fairchild, Bayer, Colgrove, 2014; Glynn, 2014). ECIG
detractors assert that ECIGs may become widely used by nicotine-naïve individuals and may
result in nicotine-dependence (Cobb, Byron, & Abrams, 2010; Grana, 2013. The potential health
implications that may be associated with ECIGs delivering little to no nicotine (as in Vansickel
et al., 2010), delivering some nicotine (as in Farsalinos et al., 2013) or delivering nicotine levels
comparable to a tobacco cigarette (as in Spindle et al., 2015) remain unclear. Understanding how
these varying levels of nicotine delivery may impact nicotine-naïve and nicotine-dependent
individuals over a prolonged period remains unknown.
Nicotine-Naïve Individuals. Nicotine-naïve individuals include adults and adolescents
who have never initiated nicotine/tobacco use and thus are not nicotine dependent. Nicotinenaïve youth and adolescents are particularly vulnerable to ECIG experimentation as they are
often targeted by ECIG marketing (Duke et al., 2014), and may be enticed by various liquid
flavors (Zhu et al., 2014). In fact, according to one national survey, the use of ECIG use among
adolescents who have never used tobacco cigarettes, has tripled from 79,000 in 2011 to 263,000
in 2013 (Bunnell et al., 2014). Some speculate that previously nicotine-naïve individuals may
eventually become nicotine-dependent, perhaps by initiating ECIG use by first using
device/liquid nicotine combinations that deliver little nicotine and later transitioning to products
that deliver more nicotine (Cobb, Hendricks, & Eissenberg, 2015). For instance, ECIGs that
deliver low amounts of nicotine may serve as “starter products” for previously nicotine-naïve
individuals (Blank & Eissenberg, 2015; Cobb et al., 2015). Furthermore, as dependence develops
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from the use of such “starter products,” ECIG users may transition to products that deliver more
nicotine, such as combustible tobacco cigarettes (Wills, Knight, Sargent, Gibbons, Pagano, &
Williams, 2016; Leventhal et al., 2015).
Nicotine-Dependent Individuals. While ECIGs are not marketed in the United States as
cessation medications for cigarette smokers, many cigarette smokers are attempting to quit or
reduce cigarette consumption through the use of these products (Grana, Popova, & Ling, 2014).
In addition to the dependence-producing constituent nicotine, tobacco cigarettes contain a myriad
of toxic chemicals (e.g., tobacco-specific nitrosamines, polycyclic aromatic hydrocarbons, and
CO) that are implicated in various smoking related diseases and disorders (e.g., cardiovascular
disease and cancers; Hecht, Carmella, Murphy, Akerkar, Brunnemann, & Hoffmann, 1993;
Hoffmann & Hecht, 1985; Lakier, 1992; USDHHS, 2014). ECIGs may provide health benefits to
nicotine-dependent cigarette smokers by delivering nicotine without the harmful constituents
emitted from combustible tobacco cigarettes, thus presenting far fewer negative health
consequences (Goniewicz et al., 2014; Polosa, Rodu, Caponnetto, Magila, & Raciti, 2013).
However, in order for nicotine-dependent cigarette smokers to switch completely to using
ECIGs, these devices will likely need to deliver nicotine in a reliable manner and with a delivery
profile (e.g., speed, dose) that is comparable to a tobacco cigarette (Cobb et al., 2015).
The extent to which ECIGs can deliver nicotine with a profile that resembles a
combustible tobacco cigarette particularly is important for nicotine-dependent smokers
attempting to quit cigarette use entirely, or those seeking an alternative nicotine delivery product.
For cigarette smokers trying to quit using ECIGs, products that deliver low amounts of nicotine
may not facilitate complete cessation and thus may prolong tobacco cigarette use (Cobb et al.,
2015). Conversely, ECIGs that deliver excessively high amounts of nicotine to the user may
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promote further nicotine dependence (Blank & Eissenberg, 2015; Cobb et al., 2015), making
quitting more difficult, or result in acute nicotine toxicity (Bartschat et al., 2015; Durmowicz,
Rudy, & Chen, 2015). Thus, ideally, ECIGs should be designed such that they can deliver
enough nicotine to substitute completely for more harmful products, like tobacco cigarettes, but
not in a manner that will deliver nicotine at levels that will be toxic to any user or increase one’s
dependence on nicotine (Shihadeh & Eissenberg, 2015).
Summary. The rapid growth in ECIG popularity among nicotine-naïve individuals and
nicotine-dependent cigarette smokers can have important individual and public health
implications. Few systematic clinical evaluations of ECIGs have been conducted, leaving many
questions regarding the factors that influence their nicotine delivery profile unanswered. Clinical
laboratory studies of some ECIG products under very limited conditions have provided some
insight on nicotine yield and delivery. However, the implications of the results of these studies
are not yet understood fully. For example, the nicotine delivery from ECIGs varies considerably
and may be dependent on the device and user behavior (e.g., puff topography). Additionally,
there may be variability in nicotine delivery among ECIG-experienced and -naïve individuals
(Farsalinos et al., 2015).
Need for Systematic ECIG Evaluation
Because ECIGs contain nicotine that is derived from the tobacco plant, they are
considered tobacco products in the U.S. ECIG use is growing in popularity among various
populations. ECIG nicotine delivery is of particular concern for regulatory agencies as ECIGs are
being used by both nicotine-naïve individuals and by nicotine-dependent tobacco cigarette users
(hoping to quit or reduce).
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Systematic Evaluation of ECIGs. To date, no studies have evaluated systematically the
nicotine delivery profile of ECIGs in ECIG-experienced and -naïve individuals. Systematic
evaluation would require holding certain factors constant (e.g., device features) while
manipulating others (e.g., liquid nicotine concentration and user experience). With systematic
evaluation, the manipulated variables could be considered to be influencing outcomes of interest.
The present study seeks to evaluate the nicotine delivery and puff topography of ECIGs in
humans while holding device features constant and manipulating user experience and liquid
nicotine concentrations.
Statement of the Problem
The rapid growth in ECIG popularity among nicotine-naïve individuals and nicotinedependent cigarette smokers can have important individual and public health implications. Few
systematic clinical evaluations of these products have been conducted, leaving many questions
regarding the factors that influence their nicotine delivery profile unanswered. Clinical
laboratory studies of some ECIG products under very limited conditions have provided some
insight on nicotine yield and delivery. However, the implications of the results of these studies
are not yet understood fully. For example, much of the ECIG research has suggested that
nicotine delivery from these devices varies considerably and may be dependent on the device and
user behavior (e.g., puff topography). Additionally, studies suggest that there may be variability
in nicotine delivery among ECIG-experienced and -naïve individuals (Farsalinos et al., 2015). As
previously mentioned, ECIG-experienced and -naïve individuals have demonstrated differences
in nicotine delivery when using comparable devices (Vansickel & Eissenberg, 2013; Farsalinos
et al., 2014). Puff topography analysis may explain some of these differences and computerized,
mouthpiece- based puff topography (as used in previous clinical lab studies; e.g., Spindle et al.,
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2015) may facilitate this understanding. Currently, no published studies have evaluated the
effects of user experience, puff topography, and various liquid nicotine concentrations on a
user’s ability to obtain nicotine. Additionally, no studies have manipulated liquid nicotine
concentration and user experience systematically, while holding device features constant.
The Present Study
This clinical laboratory study examined puff topography among ECIG-experienced and naïve individuals with four different liquid nicotine concentrations (0, 8, 18, and 36 mg/ml)
while holding all other device and liquid factors constant. Additionally, this study examined the
extent to which liquid nicotine concentration and puff topography influenced nicotine delivery in
ECIG-experienced versus -naïve individuals.
Statement of Hypothesis
The three main hypotheses of this study were as follows: 1) ECIG-experienced
individuals will obtain higher plasma nicotine concentrations compared to ECIG-naïve tobacco
cigarette smokers and 2) ECIG-experienced users will take longer and larger puffs compared to naïve individuals 3) there will be a direct relationship between liquid nicotine concentration and
plasma nicotine concentration.
Method
Selection of Participants
A total of 129 individuals met the initial study screening criteria via a telephone or online
interview, and provided informed consent for the study. Sixty four of these individuals were not
included in the final analyses as they were ineligible or discontinued. Of these individuals, 41
were determined to be ineligible at screening (3 ECIG-experienced; 38 -naïve individuals) and
never began a session. Additionally, 22 individuals began the study (7 ECIG-experienced; 15 -
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naïve individuals) but were discontinued prior to completion for the following reasons: 10 were
discontinued due to failure to attend sessions, 6 were discontinued due to lack of venous access,
3 were discontinued due to non-compliance, 1 was discontinued after experiencing an adverse
event (nausea), 1 exhibited elevated blood pressure, and 1 exhibited elevated heart rate.
Furthermore, one participant (ECIG-naïve individual) completed all four study sessions but was
not included in the final analyses when data demonstrated that the participant failed to comply
with the study puffing protocol (10 puffs with 30 s IPI).
Thus, thirty-three ECIG-experienced and 31 -naïve (cigarette smokers) community
volunteers completed all four sessions and were included in analyses for this between- and
within-subject study. An a priori power analysis indicated that this number of participants per
group would be sufficient to obtain a power of at least 0.80 (i.e., provide 80% chance of
detecting an effect). This sample size was estimated using the means and standard deviations
(SD) for two key outcome measures (plasma nicotine levels and puff duration) from two
previous studies with ECIG users and tobacco cigarette smokers (Farsalinos et al., 2013;
Farsalinos et al., 2015), using the SAS PROC POWER procedure (SAS Institute Inc., Cary, NC,
USA).
For the outcome measure of plasma nicotine, to determine effects within groups
(assuming correlations across measures of 0.6-0.8), a sample size of 16-26 participants per group
were required. To determine effects for plasma nicotine between groups, data from a previous
study comparing plasma nicotine in with ECIG users and tobacco cigarette smokers was used
(Farsalinos et al., 2015) using the same procedure described above. From the literature, the mean
(SD) plasma nicotine concentration of 7.9 ng/ml (0.9) for ECIG-experienced and 4.3 ng/ml (0.7)
for -naïve individuals were used and it was determined that with a sample size of 20 participants

29

(10 per group) a medium effect with 80 % power could be detected (alpha < .05). From the
literature, the mean (SD) puff duration of 4.2 s (0.7) for ECIG-experienced and 2.3 s (0.5) for naïve individuals were used and with a sample size of 8 participants (4 per group), and
determined that we would be able to detect a medium effect with 80% power (alpha < .05).
Participants were recruited by Institutional Review Board (IRB)-approved advertisements
and/or word-of-mouth. All experimental sessions took place at the Clinical Behavioral
Pharmacology Laboratory (CBPL) located on Virginia Commonwealth University’s (VCU)
medical campus. The CBPL is part of VCU’s Center for the Study of Tobacco Products (CSTP).
In order to be eligible for the study, participants had to be healthy, aged 18-55, and provide their
informed consent to the use of study products after having abstained from nicotine/tobacco for at
least 12 hours.
Two distinct populations (ECIG-experienced and -naïve individuals) were sampled for
this study and had different eligibility criteria; see Table 2 for demographic information by
group. In order to be eligible for the study ECIG-experienced individuals had to report the use
of ≤ 5 conventional tobacco cigarettes daily (M = 0.2; SD = 0.8), use ≥ 1 ml of ECIG solution
daily (M = 3.3; SD = 3.7), use ECIG solution with a nicotine concentration ≥ 8 mg/ml (M = 17.5;
SD = 5.4; see Table 3), use their ECIG for ≥ 3 months (M = 17.1; SD = 9.9), and provide an
expired CO sample with a concentration ≤ 10ppm at screening (M = 3.0; SD = 2.1; suggestive of
non-smoking status). To be eligible for the study, ECIG-naïve tobacco cigarette smokers had to
use ≥ 10 conventional tobacco cigarettes daily (M = 16.5; SD = 9.4) have < 5 ECIG uses in their
lifetime (M = 2.0; SD = 1.5), and provide a CO sample with a concentration ≥15 ppm during
screening (M = 19.9; SD = 5.6; suggestive of current smoker status).
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Individuals (in either group) who self-reported the following were excluded from
participation: chronic disease or current, diagnosed psychiatric condition or regular use of a
prescription medication (with the exception of vitamins and birth control). Individuals who
weighed less than 110 pounds were also excluded as the study involves multiple blood draws and
involves self-administration of potentially high nicotine concentration during certain study
conditions. Individuals using marijuana > 10 days in the past 30 or using alcohol > 25 days in the
past 30 were excluded. Past month use of cocaine, opioids, benzodiazepines, and
methamphetamine was exclusionary and women were excluded if currently breast-feeding or if
they tested positive for pregnancy at screening.
As expected, ECIG-experienced and -naïve individuals differed on several demographic
characteristics pertaining to eligibility criteria (see Table 2) such that ECIG-experienced
individuals smoked fewer cigarettes per day and had lower CO levels at screening relative to
ECIG-naïve individuals. ECIG-experienced and-naïve individuals also differed on some
demographic characteristics that did not pertain to the differing eligibility criteria. Fewer ECIGexperienced women completed this study (N = 6) relative to ECIG-naïve (N = 13). Also, ECIGexperienced individuals had significantly lower scores on the Penn State Dependence
Questionnaire at screening (M = 9.9; SD = 3.4) relative to ECIG-naïve individuals (M = 12.2;
SD = 4.0).
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Table 2.
Results of Statistical Analyses for Demographic Data by Group.

Number Female
Number Caucasian

ECIG-experienced
N = 33
Mean or
SD
N
6
24

ECIG-naïve
N = 31
Mean or
SD
N
13
16

t-statistic

p value

-2.1a

<.05

-1.8a

n.s.

Age (years)

30.3

8.4

30.8

9.9

-0.3a

n.s.

Screen CO

3.0

2.1

19.9

5.6

-16.2a

<.05

Cigarettes/day

0.2

0.8

16.5

9.4

-10.0a

<.05

Volume liquid used/day (ml)

3.3

3.7

N/A

N/A

N/A

N/A

Liquid concentration (mg/ml)

17.5

5.4

N/A

N/A

N/A

N/A

Duration cigarette use (months)

2.0

10.6

110.3

113.9

-5.4a

<.05

Duration ECIG use (months)

17.1

9.9

N/A

N/A

N/A

N/A

Fagerström TNDc

4.3

2.0

4.7

1.9

-0.8a

n.s.

Penn State Dependenced

9.9

3.4

12.2

4.0

-2.0b

<.05

Number choosing menthol

12

-2.0a

n.s.

19

Note: n.s. = not significant; N/A refers to not applicable to that particular group.
a

df = 62; b df = 57

c

The Fagerström Test for Nicotine Dependence (Heatherton et al., 1986)

d

Penn State Electronic Cigarette Dependence Index (Foulds et al., 2014)
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Table 3.
ECIG Device and Solution Characteristics (Based on Product Labeling and Manufacturer
Information).
Participant

ECIG model

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33

e-Go
Kanger
e-Go
e-Go T
i-Taste
e-Go T
e-Go T
e-Go
i-Taste
iStick e-leaf
e-Go
e-Go T
e-Go T
Voodoo Vape
e-Go T
Vamo V5
i-Taste
e-Go
e-Go
i-Taste
iStick e-leaf
e-Go
e-Go
i-Taste
Vision Spinner
Grenco G-Pro
IPV
e-Go
e-Go
e-Go
MVP Pro
MVP Pro
e-Vic

Nicotine
Concentration
(mg/ml)
24
18
18
12
12
24
12
18
18
24
28
12
25
16
28
18
12
18
12
18
24
18
12
18
18
12
12
12
12
12
24
24
12

Solvent
ratio:
PG/VG
50/50
80/ 20
N/A
30/70
50/50
0/100
30/70
30/70
30/70
60/40
50/50
50/50
60/40
30/70
30/70
30/70
40/60
70/30
70/30
40/60
40/60
40/60
50/50
40/60
30/70
30/70
30/70
30/70
65/35
65/35
65/35
65/35
65/35

Battery
Voltage
(selfreport)
unknown
unknown
4.2
unknown
unknown
unknown
3.3
3.3
3.3
unknown
3.7
3.7
unknown
3.7
unknown
3.7
3.7
3.7
unknown
unknown
3.3
9.0
2.0
3.3
3.3
4.2
3.2
3.7
4.0
4.0
4.0
4.0
4.0

Liquid Flavor

Peach
DK Blend
Menthol
Persian Winter
Van. Dr. Pepp.
Gorilla Juice
Gold Rush
Aztec
Cinnan-toast
Carolina Crush
Pink Tornado
Mnky Business
Carolina Cured
White Mousee
Persian Winter
Persian Winter
Spearmint
Blueberry
Vanilla
Pomegranate
Wintergreen
Colonel Custard
Vanilla
King’s barrel
Cowboy Cut
Unicorn Milk
Cont. Breakfast
Smerf Vendetta
Jungle Juice
Jungle Juice
Jungle Juice
Jungle Juice
Jungle Juice
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Screening and Informed Consent Procedures
Interested individuals participated in a two-part screening process. First, they participated
in a phone interview or online survey where they were asked about their health status, tobacco
use, and ECIG use (see appendix A). Potentially eligible individuals who met the requirements
for the study were asked to come to the laboratory for an in-person screening which began with
an informed consent process (see appendix B). Once informed consent was obtained, individuals
provided further information about their health, tobacco use, ECIG use, and demographic
information and women provided urine for an immediate pregnancy test (Accutest Value hCG
urine pregnancy test, Jant Pharmaceutical Corp). Lastly, participants provided a breath sample
for analysis of expired air CO concentration to determine eligibility as described above. Eligible
participants sampled two ECIG liquid flavors (menthol or tobacco; 0 mg/ml nicotine) and
selected one of them for use in all subsequent sessions. Tobacco and menthol flavors were
chosen for this study because they have been identified as two of the four most popular ECIG
flavors, especially among tobacco cigarette smokers who have recently initiated ECIG use
(Dawkins, Turner, Roberts, & Soar, 2013; Farsalinos, Romagna, Tsiapras, Kyrzopoulos, Spyrou,
& Voudris, 2013).
Materials
In each session, participants used an “eGo” 3.3 volt, 1000 mAh ECIG battery attached to
a 1.5 Ohm, dual-coil, 510-style “cartomizer”. The cartomizer was pre-loaded with 1 ml of a
flavored solution (tobacco or menthol), that was comprised of 70% propylene glycol/30%
vegetable glycerin and contained 1 ml of one of four liquid nicotine concentrations: 0, 8, 18, or
36 mg/ml. All liquid was purchased from a local ECIG vendor, Avail (Richmond, VA) and
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liquid nicotine concentration was verified prior to administration. All cartridges were produced
by SmokTech (Shenzhen, China) and purchased online.
Procedures
After the completion of screening procedures, participants attended the laboratory on four
days (separated by a minimum of 48 hours) for four, randomized, double-blind, independent
laboratory sessions that lasted approximately 2.5 hours each. Sessions differed only by the liquid
nicotine concentration placed in the cartomizer (0, 8, 18, or 36 mg/ml). Twelve-hour abstinent
participants provided expired air CO concentration at the beginning of each session in order to
verify abstinence from combustible tobacco (≤ 10 ppm, as in Breland et al., 2002). Participants
who did not meet the expired air CO concentration for abstinence tobacco (≤ 10 ppm) were not
allowed to participate in the session that day. Under normal conditions, ECIGs do not produce
CO as they are not combustible like tobacco cigarettes. Therefore, abstinence from nicotinecontaining products was verified retrospectively in ECIG-experienced individuals using baseline
plasma nicotine concentration (the criterion used to indicate abstinence was < 5 ng/ml).
At the beginning of each session expired air CO concentration was measured to ensure
participants had abstained from combustible tobacco (≤ 10 ppm, as in Breland et al., 2002).
Immediately after, the monitoring of physiological responses such as heart rate (HR) and blood
pressure (BP) began. Then, a nurse inserted a catheter into a forearm vein. Thirty minutes
following catheter insertion, 7ml of blood was sampled (-5 min) followed by the completion of
computerized questionnaires intended to assess tobacco abstinence symptoms and other
subjective effects (see Figure 2). After collection of baseline blood and subjective questionnaires
the first of two directed ECIG-use bouts (separated by 60 minutes) began. Participants were
instructed to take 10 puffs from the provided ECIG, with each puff separated by 30 s. As
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mentioned previously (see introduction), puff count (i.e., the number of puffs taken) and IPI are
often standardized. In the present study, IPI is defined as the time between the onset of one puff
and the onset of a subsequent puff (as seen in Vansickel et al., 2010, Farsalinos et al., 2014;
Spindle et al., 2014). The 10 puff bout was monitored and verified by a trained research assistant
who directed the participant and ensure that puffs were taken at the correct time. Immediately
following the final puff of the first bout, the second 7 ml of blood was sampled (+5 min) and
subjective questionnaires were administered again. Blood samples 3 (+15 min), 4 (+30 min) 5
(+45 min), and 6 (+55 min) were collected, each followed by subjective questionnaires.
Following the sixth blood sample (60 minutes after the first directed bout) the second bout
began. Immediately following the final puff of the second bout, a 7th 7 ml of blood was sampled
(+65 min), followed by blood samples 8 (+75 min), 9 (+90 min), and 10 (+105min). Each of
these samples was also followed by administration of the subjective questionnaires (see Figure
2).
After the completion of the tenth set of subjective measures, physiological data collection
was discontinued, the catheter was removed, and participants were compensated (US $75 after
first session, $75 after second, $150 after the third and $200 after the fourth session).
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Figure 2. Session procedure involved participants visiting the laboratory for four, 2.5 hour
sessions. Prior to each session, at least 12 hours of abstinence from nicotine/tobacco was
required, and was verified by a pre-session CO reading of < 10 ppm. After participants met this
requirement, physiological monitoring commenced, an intravenous catheter was inserted into a
forearm, and the session began.

37

Participant Safety and Rights
The study methods and procedures described above have been used in this laboratory for
over 15 years. While 12 hours of nicotine/tobacco abstinence may be uncomfortable, it is not
medically dangerous and does not pose a threat to participant safety. Additionally, the blood
sampling procedure that occurred via an intravenous catheter involved minimal risk of bruising
or infection. This laboratory’s trained nursing staff used aseptic nursing procedures and sterile,
disposable equipment in order to minimize risk. The use of ECIGs/nicotine also posed minimal
risk as the target population had experience with either ECIGs or conventional tobacco
cigarettes.
The experienced CBPL staff is trained to ensure that participant safety and rights were
maintained throughout the duration of the study. Both heart rate (HR) and blood pressure (BP)
were monitored closely and sessions were discontinued if a participant’s systolic BP elevated
above 140 or dropped below 90 or if their HR elevated above 120 or dropped below 50.
Confidentiality of data was maintained and participant data was identified using an alphanumeric
code only and stored in locked rooms accessible only by CBPL staff.
Outcome Measures
Physiological Measures. All blood samples were centrifuged, stored at -70°C, and
analyzed for nicotine concentration (limit of quantitation (LOQ) = 2 ng/ml; see Breland et al.,
2006) by VCU’s Bioanalytical Analysis Core Laboratories. Using Criticare Systems model 507,
fitted with pulse oximeter, HR was monitored every 20 s. Participants’ expired air CO
concentration was measured via a BreathCO monitor (Vitalograph, Lenexa, KS).
Puff Topography. Using an ECIG topography instrument developed and manufactured
at the American University of Beirut (AUB; see Spindle et al., 2015), puff topography was

38

measured throughout each ECIG bout. Puff topography measurements included: puff duration,
volume, flow rate (a.k.a. puff velocity), number and IPI (i.e., the time between puff onset and the
puff onset of the subsequent puff). This instrument is comparable to cigarette topography
instruments (e.g., CReSS, see introduction and Blank, 2009) and has been tested to determine
that the equipment does not interfere with nicotine delivery or abstinence symptom suppression
(see Spindle et al., 2015).
This device uses mouthpieces, several of which were manufactured for this study and the
device was calibrated with the mouthpiece attached prior to each session using a custom built
automatic digital flow calibrator. The orifice dimensions of each mouthpiece and pressuresensing transducer provided sensitivity sufficient to ensure valid measurements at puff velocities
as low as 3 ml/sec because tobacco cigarette topography devices may not be sensitive enough to
measure ECIG topography accurately (Eissenberg, 2014).
Subjective Questionnaires. Four subjective measures (Hughes-Hatsukami Scale, The
Direct Effects of ECIG Use Questionnaire, Acceptability Questionnaire, and Tiffany-Drobes
Questionnaire of Smoking Urges) were administered at ten separate time points. Three of these
questionnaires were administered using a computerized visual analog scale (VAS) which
consisted of a word or phrase centered on a horizontal line with “not at all” on the left and
“extremely” on the right. Participants recorded responses by clicking a mouse at any point on a
horizontal line and scores were expressed as a percentage of total line length.
Hughes-Hatsukami Withdrawal Scale. An adapted version of this VAS measure was
used for this study (see Breland, Evans, et al., 2002, Buchhalter et al., 2005) intended to assess
nicotine abstinence symptom suppression and was composed of 11 items: “Anxious,” “Craving
and e-cigarette/nicotine,” “Depression,” “Difficulty concentrating,” “Drowsy,” “Hunger,”
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“Impatient,” “Irritable,” “Restlessness,” “Desire for sweets,” and “Urge to smoke.” ECIGexperienced and ECIG-naïve cigarette smokers received the exact same scale with the exception
of the measure “Urge to Smoke,” which was adjusted to “Urge to use an ECIG” for ECIGexperienced users (Hughes & Hatsukami, 1986, see appendix C).
Direct Effects of ECIG Use. This 10-item VAS measure, adapted from the “Direct
Effects of Tobacco” scale, was developed with items reported in studies assessing the subjective
effects of smoking (e.g., Foulds et al., 1992; Pickworth, Bunker, & Henningfield, 1994). This
scale assessed the subjective effects of ECIG use: “Did the e-cigarette make you feel more
awake?,” “ Did the e-cigarette help calm you down?,” “Did the e-cigarette help with
concentration?,” “Did the e-cigarette make you dizzy?,” “Was the e-cigarette pleasant?,” “Did
the e-cigarette reduce hunger?,” “Would you like another e-cigarette right now?,” “Was the ecigarette satisfying?,” “Did the e-cigarette make you sick?,” and “Did the e-cigarette taste
good?”
Acceptability Questionnaire. Finally, because topography was measured in each
condition this VAS measure assessed the degree to which the topography equipment: “Alters ecigarette use behavior,” “Makes vaping less likely,” “Reduces enjoyment,” “Affects e-cigarette
taste,” “Increases awareness,” and “Increases vaping difficulty” (as in Blank et al., 2009; Spindle
et al., 2015).
Tiffany-Drobes QSU Brief. The QSU Brief consisted of 10 smoking-related items: “I
have a desire for a cigarette/ECIG right now,” “Nothing would be better than smoking a
cigarette/ECIG right now,” “If it were possible, I would probably smoke/use an ECIG right
now,” I could control things better right now if I could smoke/smoke an ECIG,” “All I want right
now is cigarette/ECIG,” “I have an urge for a cigarette/ECIG,” “Smoking/an ECIG would make
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me less depressed,” and “ I am going to smoke/ use an ECIG as soon as possible” (Cox, Tiffany,
& Christen, 2001). Smoke/smoking was substituted with ECIG/use an ECIG for ECIGexperienced participants. Participants rated each item on a 7-point scale ranging from 0 (Strongly
disagree) to 7 (Strongly agree). The items form two factors: Factor 1 (intention to smoke) and
Factor 2 (anticipation of relief from abstinence symptoms).
Data Analysis Plan
The outcome measures for this thesis are plasma nicotine concentration, puff topography,
and heart rate. Other measures are not a focus for this thesis and are not discussed further. For
plasma nicotine, values below the limit of quantification (LOQ) were replaced with the LOQ (2
ng/ml; as in Vansickel et al., 2010), as this is a more conservative approach compared to
identifying each value below the LOQ as zero. For plasma nicotine concentration, missing data
values were imputed by replacing the missing value with an average of the value before and after
the missing plasma nicotine concentration value (of the 2,560 plasma nicotine values, only 3
were missing). Topography equipment generated values for puff velocity data to produce the
topography measures puff duration, puff volume, mean puff velocity, puff number, and IPI (see
Shihadeh, Azar, Antonios, & Haddad, 2004). A data cleaning procedure was performed that
combined two or more puffs separated by less than 100 ms into a single puff and deleted any
puffs less than 300 ms (Spindle et al., 2015). For topography data, no missing values for any of
the variables were observed. Prior to analysis, HR data were averaged to produce a single value
for baseline and the five minutes during each ECIG-use bout (3 values in total per session
referred to as Baseline, Bout 1, and Bout 2). For HR, any missing values were replaced by the
HR measurement that was recorded manually during each individual participant’s session.
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Statistical analyses for the three primary outcome measures (plasma nicotine, puff
topography, and HR) were performed using IBM SPSS (Version 23.0). Mixed Analysis of
Variance (ANOVAs) were used to examine plasma nicotine, topography, and HR data. For
plasma nicotine, a mixed ANOVA with group as a between-subject factor (ECIG-experienced or
-naïve individuals) and liquid nicotine concentration (hereafter referred to as “condition”; 4
levels) and time (10 levels) as within-subject factors was conducted. For puff topography, for
each measure, a mixed ANOVA with group as a between-subject factor (ECIG-experienced or naïve) condition (4 levels) and bout (2 levels) as within-subject factors was conducted. Finally,
for HR, a mixed ANOVA with group as the between-subject factor (ECIG-experienced or naïve) and condition (4 levels) and time (3 levels; baseline, HR average during bout 1 and HR
average during bout 2) as within-subject factors was conducted.
In order to understand whether gender may influence key outcome measures, all data
were also analyzed using mixed ANOVAs with gender as the between-subject factor (male or
female) and condition (4 levels) and time (10 levels for plasma; 2 levels for topography
variables; 3 for HR variables) as the within-subject factors. For ECIG-experienced individuals,
27 of 33 were men and for ECIG-naïve individuals 18 of 31 were men.
While the effects of flavor on plasma nicotine concentration following acute ECIG use
have not been evaluated thoroughly, some studies suggest that flavor may influence plasma
nicotine concentration (Oncken, Litt, McLaughlin, & Burki, 2015). In order to understand
whether or not ECIG-liquid flavor may influence key outcome measures, all data were analyzed
using mixed ANOVAs with flavor as the between-subject factor (menthol or tobacco) and
condition (4 levels) and time (10 levels for plasma; 2 levels for topography variables; 3 for HR)
as the within-subject factors. Prior to the start of all four sessions, participants in each group
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were given the option of selecting either menthol or tobacco flavored ECIG-liquid. Ultimately,
21 ECIG-experienced individuals selected tobacco flavor and 12 selected menthol. Of the ECIGnaïve individuals, 12 selected tobacco flavor and 19 selected menthol.
ANOVAs are susceptible to violations of assumptions of sphericity. Sphericity violations
occur when the variances between all combinations of related groups are unequal. Violations to
sphericity can result in an increase in the Type I error rate if not corrected. The Huynh-Feldt
(1976) procedure is a correction generated to adjust for sphericity violations. For all repeated
measures factors, significance levels were adjusted for potential violations of sphericity using
Huynh-Feldt corrections (Huynh & Feldt, 1976).
For all outcome measures, within-subject comparisons were made using Tukey’s
Honestly Significant Difference (HSD) test, based on the studentized range distribution, to
compare all possible pairs of means (Tukey, 1949). Between-subject (i.e., ECIG-experienced
versus -naïve individuals) comparisons were made using planned contrasts using independent
samples t-tests. For plasma nicotine concentration, planned contrasts were conducted across
groups for the time point prior to bout 1 (-5 min), immediately after bout 1 (+5 min),
immediately prior to bout 2 (+55 min) and immediately after bout 2 (+65 min). Similarly,
planned contrasts were used to make cross group comparisons for topography and heart rate
measures. Because these planned contrasts were orthogonal at each time point, no corrections
were made to type I error rate for them (Keppel, 1992).
Prior to conducting the main study analyses for plasma nicotine, topography, and HR
described above, plasma nicotine data were first inspected to determine if any participants were
not abstinent at prior to the onset of any session. That is, this study required ≥ 12 hours
abstinence from all nicotine/tobacco containing products prior to each session; this level of
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abstinence was verified retrospectively by examining pre-session plasma nicotine concentration
for each participant and each session. Five ng/ml was selected as the cutoff for 12 hours of
nicotine abstinence (i.e., individuals with a baseline plasma values of 5.0 ng/ml or higher were
consider to be not abstinent) for both ECIG-experienced and -naïve individuals (see Spindle et
al., 2016). Ultimately, 18 of the 33 ECIG-experienced and 21 of the 31 -naïve individuals were
considered to have abstained from nicotine prior to each of the four sessions. To understand how
abstinence status influenced each outcome measure within each group of participants (ECIGexperienced and -naïve individuals), and before conducting the analyses described above, all
within group data first were analyzed using mixed factorial ANOVAs with abstinence status as
the between-subject factor (abstinent or non-abstinent) and condition (4 levels) and time (10
levels for plasma; 2 levels for topography variables; 3 for HR) as the within-subject factors. In
the results below, this analysis by abstinence status preceded and in some cases informed the
overall analysis results that follow.
Results
This within and between-subject, double blind, clinical laboratory study examined the
extent to which liquid nicotine concentration and puff topography influenced nicotine delivery in
ECIG-experienced and -naïve individuals. Also, this study examined puff topography among
ECIG-experienced and -naïve individuals with four different liquid nicotine concentrations (0, 8,
18, and 36 mg/ml) while holding all other device and liquid characteristics constant.
Plasma Nicotine
The Effect of Abstinence Status. Table 4 shows the statistical analyses for plasma
nicotine using raw data to evaluate potential effects of abstinence status for ECIG-experienced
and -naïve individuals. As the table shows, for ECIG-experienced individuals there was a
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significant main effect of abstinence status [F (1, 31) = 9.8 p <.01] in addition to other
significant main effects and a significant condition by time interaction. Among those who are
ECIG-experienced, non-abstinent individuals obtained significantly higher baseline plasma
nicotine concentrations in the 8 (M = 8.1; SD = 7.4), 18 (M = 9.3; SD = 7.8) and 36 mg/ml (M =
7.1; SD = 5.2) conditions relative to abstinent individuals whose baseline plasma nicotine
concentrations were significantly lower in the 8 (M = 2.0; SD = 0.2), 18 (M = 2.1; SD = 0.3) and
36 mg/ml (M = 2.0; SD = 0.5) conditions, but not in the 0 mg/ml condition [ts (31) < -2.5; ps <
.05].
For ECIG-naïve individuals Table 4 shows a significant main effect of abstinence status
[F (1, 29) = 9.6, p <.01] in addition to other significant main effects and a significant condition
by time interaction. Non-abstinent individuals obtained significantly higher baseline plasma
nicotine concentrations in the 0 (M = 6.3; SD = 4.7), 8 (M = 4.7; SD = 3.1) and 36 mg/ml (M =
5.8; SD = 4.9) conditions relative to abstinent individuals whose baseline plasma nicotine
concentrations were significantly lower in the 0 (M = 2.4; SD = 0.6), 8 (M = 2.2; SD = 0.6) and
36 mg/ml (M = 2.4; SD = 0.8) conditions, but not in the 18 mg/ml condition [ts (29) < -2.6; ps
<.05]. The main effects of abstinence status observed for ECIG-experienced and -naïve
individuals when analyzing plasma nicotine concentration using raw data appear to indicate that
differences across abstinence status were due to baseline plasma nicotine differences.
To explore whether abstinence status influenced differences in plasma nicotine
concentration between abstinent and non-abstinent individuals after ECIG use or whether they
occurred due to baseline differences, the same analyses (i.e., mixed ANOVAs with abstinence
status as the between subject factor) were conducted using plasma nicotine concentration
difference scores (i.e., change scores from baseline for each individual in each condition). Using
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difference scores for plasma nicotine concentration eliminates baseline plasma nicotine
differences among abstainers and non-abstainers in each group (i.e., ECIG-experienced and naïve individuals). When using difference scores for plasma nicotine concentration, no
significant main effects involving abstinence status were observed for either ECIG-experienced
or -naïve individuals (see Table 4). Taken together, these results suggest that increases in plasma
nicotine observed post-ECIG use do not differ as a function of abstinence status and that the
differences observed for plasma nicotine among abstainers and non-abstainers (using raw data)
were significant due to differences in plasma nicotine concentrations at baseline. Thus, the final
analyses (presented below) for plasma nicotine concentration in ECIG-experienced and -naïve
individuals were conducted using difference scores and included all participants in the sample
(abstinent and non-abstinent).
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Table 4.
Statistical Analyses Results for Plasma Nicotine for ECIG-experienced and -naïve Individuals by Abstinence Status
Outcome measures
ECIG-experiencedª
Plasma nicotine
Raw Data
Difference Scores
ECIG-naïveb
Plasma nicotine
Raw Data
Difference Scores

Condition (C)
F value

p value

Time (T)
F value

p value

Abstinence (A)
F value

p value

C×T
F value

p value

38.0
27.2

<.001
<.001

32.7
32.7

<.001
<.001

9.8
0.4

<.01
ns

11.8
11.8

<.001
<.001

13.2
13.6

<.001
<.001

15.3
15.5

<.001
<.001

9.6
0.01

<.01
ns

4.1
3.9

<.001
<.001

Note: ns = non-significant
a

df C = (3, 93); df T = (9, 279); df A = (1, 31); df C x T = (27, 837)

b

df C = (3, 87); df T = (9, 261); df A = (1, 29); df C x T = (27, 783)
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Change from Baseline (Nicotine Boost). Among ECIG-experienced and -naïve
individuals, differences observed as a function of abstinence status using raw data were no
longer observed when difference score data were analyzed. Thus, the final analyses for plasma
nicotine concentration in ECIG-experienced and -naïve individuals were conducted using
difference score data (hereafter referred to as “nicotine boost” – the change in plasma nicotine
concentration calculated by subtracting baseline nicotine concentration from post ECIG use
plasma nicotine concentration). All participants (abstinent and non-abstinent) are included in this
analysis.
Using nicotine boost data, a significant three-way condition by time by group interaction
was observed for nicotine boost [F (27, 1674) = 2.6, p <.01]. A significant condition by time
interaction [F (27, 1674) = 15.0, p < .001], a time by group (ECIG-experienced versus -naïve)
interaction [F (9, 558) = 6.7, p < .01], and a significant condition by group interaction [F (3, 186)
= 6.7, p < .01] were also observed. Also, significant main effects of condition [F (3, 186) = 40.3,
p <.001], time [F (9, 558) = 46.4, p < .001], and group [F (1, 62) = 10.6, p < .01] were observed.
Figure 3 depicts mean nicotine boost, over time, by condition (i.e., liquid nicotine concentration)
for ECIG-experienced and -naïve individuals.
For ECIG-experienced individuals, immediately following bout 1, mean (SD) nicotine
boost for the 0 mg/ml liquid nicotine concentration was 0.01 ng/ml (1.5), for 8 mg/ml it was 8.2
ng/ml (7.8), for 18 mg/ml it was 13.0 ng/ml (6.2), and for 36 mg/ml it was 17.9 ng/ml (17.2).
Immediately following bout 2, mean nicotine boost for 0 mg/ml was -0.3 ng/ml (3.0), for 8
mg/ml it was 7.2 ng/ml (6.1), for 18 mg/ml it was 11.2 ng/ml (12.5) and for 36 mg/ml it was 14.9
ng/ml (12.4). In general, nicotine boost was significantly higher when using active liquid
nicotine concentration versus placebo (0 mg/ml). Among ECIG-experienced individuals, within-
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group comparisons revealed significant differences in nicotine boost between 0 mg/ml and the 8,
18, and 36 mg/ml conditions immediately following bout 1 and bout 2 (Tukey’s HSD, p < .05).
Also, significant differences in nicotine boost were observed between the 8 and 36 mg/ml
conditions immediately following bouts 1 and 2. No significant differences in nicotine boost
were observed between 8 and 18 mg/ml or 18 and 36 mg/ml conditions following bout 1 or 2.
For ECIG-naïve individuals, immediately following bout 1, mean (SD) nicotine boost for
the 0 mg/ml liquid nicotine concentration was -0.02 ng/ml (1.5), for the 8 mg/ml it was 3.6 ng/ml
(3.9), for 18 mg/ml it was 6.2 ng/ml (10.2), and for 36 mg/ml it was 6.8 ng/ml (7.1). Immediately
following bout 2, mean nicotine boost for 0 mg/ml was -0.4 ng/ml (2.5), for 8 mg/ml it was 4.8
ng/ml (8.0), for 18 mg/ml it was 6.0 ng/ml (10.3) and for 36 mg/ml it was 7.4 ng/ml (9.2). In
general, nicotine boost was significantly higher when using active liquid nicotine concentration
versus placebo (0 mg/ml). Among ECIG-naive individuals, within-group comparisons revealed
significant differences in nicotine boost between 0 and 18 mg/ml and between 0 and 36 mg/ml
immediately after bout 1 and 2 (Tukey’s HSD, p < .05). No significant differences in nicotine
boost between the 0 and 8 mg/ml, 8 and 18 mg/ml or 18 and 36 mg/ml conditions were observed
following bout 1 or 2 (see Figure 3).
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Plasma Nicotine Boost
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Figure 3. Mean (± SEM) nicotine boost for ECIG-experienced (N = 33) and -naïve individuals (N
= 31). Arrows indicate the onset of each 10-puff ECIG use bout. Filled symbols indicate a
significant difference from baseline (-5 time point), asterisks (*) indicate significant differences
from the 36 mg/ml nicotine concentration at that time point (note the figure displays comparisons
for the 36 mg/ml concentration for time 5 and time 65 only, see the text for more comparisons; ps
< .05; Tukey’s HSD). Plus signs (+) indicate significant between group differences at that time
point for that concentration (independent t-tests; ps < .05).
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Across groups, for nicotine boost, planned contrasts were conducted for the time point
prior to bout 1 (-5 min), immediately after bout 1 (+5 min), immediately prior to bout 2 (+55
min) and immediately after bout 2 (+65 min) and revealed significant between group (ECIGexperienced versus -naïve) differences in the 8, 18, and 36 mg/ml conditions [ts (62) < -0.17; ps
<.05] but not in the 0 mg/ml condition. ECIG-experienced individuals obtained significantly
higher nicotine boost immediately following bout 1 in the 8 (M = 8.2; SD = 7.8), 18 (M = 13.0;
SD = 13.2) and 36 mg/ml (M = 17.9; SD = 17.2) conditions relative to ECIG-naïve individuals
who had significantly lower nicotine boost immediately following bout 1 in the 8 (M = 3.6; SD =
3.9), 18 (M = 6.2; SD = 10.2) and 36 mg/ml (M = 6.9; SD = 7.1) conditions, but not in the 0
mg/ml condition. Immediately following bout 2, ECIG-experienced individuals obtained
significantly higher nicotine boost in the 18 (M = 11.2; SD = 12.5) and 36 mg/ml (M = 14.9; SD
= 12.4) conditions relative to ECIG-naïve individuals whose nicotine boost was significantly
lower following bout 2 in the 18 (M = 6.0; SD = 10.3) and 36 mg/ml (M = 7.4; SD = 9.2). Taken
together, these results support the notion that the significant three-way interaction arises from the
fact that, although both groups started at the same baseline, ECIG-experienced participants had
higher nicotine boost, on average, after each bout in many active nicotine conditions.
In an additional analysis used to help clarify results, a mean peak nicotine boost value
was calculated for each group (ECIG-experienced and -naïve) for each condition (0, 8, 18, and
36 mg/ml liquid nicotine concentration) for both bout 1 and bout 2. That is, for each individual
participant, in each condition, a peak nicotine boost value was calculated for bouts 1 and 2. The
individual peak nicotine boost were then averaged across all participants to produce a single peak
nicotine boost value for each condition and group. Figure 4 depicts peak nicotine boost for each
condition and bout by group. Planned contrasts were conducted to compare mean peak nicotine
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boost in each condition across groups (ECIG-experienced and -naïve). For bout 1, significant
between group differences were observed in the 8, 18, and 36 mg/ml conditions such that ECIGexperienced individuals obtained significantly higher mean peak nicotine boost immediately
following bout 1 in the 8 (M = 8.5; SD = 7.6), 18 (M = 13.7; SD = 12.4) and 36 mg/ml (M =
20.0; SD = 16.4) conditions relative to ECIG-naïve individuals who obtained significantly lower
mean peak nicotine boost immediately following bout 1 in the 8 (M = 4.0; SD = 4.0), 18 (M =
7.2; SD = 9.8) and 36 mg/ml (M = 7.6; SD = 7.2) conditions, but not in the 0 mg/ml condition [ts
(62) > 2.3; ps <.05].
For bout 2, significant between group differences were observed such that ECIGexperienced individuals obtained significantly higher mean peak nicotine boost immediately
following bout 2 in the 18 (M = 12.6; SD = 12.0) and 36 mg/ml (M = 17.0; SD = 12.7)
conditions relative to ECIG-naïve individuals whose peak nicotine boost were significantly
lower in the 18 (M = 6.7; SD = 10.0) and 36 mg/ml (M = 8.8; SD = 9.0) conditions, but not in
the 0 or 8 mg/ml condition. [ts (62) > 2.1; ps <.05]
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Mean Peak Plasma Nicotine Boost by Bout
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Figure 4. Mean (± SEM) peak nicotine boost derived using difference scores for ECIGexperienced (N = 33) and ECIG-naïve individuals (N = 31) by condition and bout (see text for
details of how data were prepared for this analysis). Plus signs (+) indicate significant between
group differences at that condition for that bout (independent t-tests; ps < .05).
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The Effect of Gender. To explore whether gender influenced nicotine boost within each
group (ECIG-experienced or -naïve) the same analyses (i.e., mixed ANOVAs with gender as the
between-subject factor) were conducted using nicotine boost data (i.e., change scores from
baseline).
For ECIG-experienced individuals a significant condition by time interaction was
observed [F (27, 837) = 11.8, p <.001] but no significant main effects or interactions involving
gender were observed, thus, further analyses were not conducted. For ECIG-naïve individuals a
significant three way condition by time by gender interaction was observed [F (27,783) = 2.1, p
<.05] for nicotine boost. Also, significant condition by time [F (27,783) = 4.2, p <.001] and
significant condition by gender [F (3, 87) = 6.2, p <.01] interactions were observed.
For ECIG-naïve women, immediately following bout 1, mean (SD) nicotine boost for the
0 mg/ml liquid nicotine concentration was -0.0 ng/ml (0.6), for 8 mg/ml it was 1.5 ng/ml (2.4),
for 18 mg/ml it was 1.7 ng/ml (3.5), and for 36 mg/ml it was 4.1 (5.7). Immediately following
bout 2, mean nicotine boost for 0 mg/ml was -0.6 ng/ml (3.5), for 8 mg/ml it was 4.7 ng/ml
(11.6), for 18 mg/ml it was 1.9 ng/ml (3.0) and for 36 mg/ml it was 2.8 ng/ml. Among ECIGnaïve women, none of the mean nicotine boost for any condition differed significantly from
baseline. Also, no differences across bouts 1 and 2 were detected for any condition.
For ECIG-naïve men, immediately following bout 1, mean (SD) nicotine boost for the 0
mg/ml liquid nicotine concentration was -0.01 ng/ml (1.9), for the 8 mg/ml it was 5.1 ng/ml
(4.1), for 18 mg/ml it was 9.4 ng/ml (12.2), and for the 36 mg/ml it was 8.9 ng/ml (7.5).
Immediately following bout 2, mean nicotine boost for 0 mg/ml was -0.3 ng/ml (1.5), for 8
mg/ml it was 4.8 ng/ml (4.1), for 18 mg/ml it was 8.9 ng/ml (12.6) and for 36 mg/ml it was 10.6
ng/ml (10.0). Significant differences in nicotine boost were observed between 0 and 18 mg/ml
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and between 0 and 36 mg/ml immediately after bout 1 and bout 2 (Tukey’s HSD; ps < .05). No
significant differences in nicotine boost were observed between 0 and 8 mg/ml, 8 and 18 mg/ml
or 18 and 36 mg/ml following bout 1 or 2.
Across gender for ECIG-naïve individuals, planned contrasts were conducted for nicotine
boost for the time point prior to bout 1 (-5 min), immediately after bout 1 (+5 min), immediately
prior to bout 2 (+55 min) and immediately after bout 2 (+65 min). Planned contrasts revealed
significant gender differences such that men obtained significantly higher nicotine boost
immediately following bout 1 in the 8 (M = 5.1; SD = 4.1), 18 (M = 9.4; SD = 12.2) and 36
mg/ml (M = 8.9; SD = 7.57) conditions, relative to women who obtained significantly lower
nicotine boost in the 8 (M = 1.5; SD = 2.4), 18 (M = 1.7; SD = 3.5) and 36 mg/ml (M = 4.1; SD
= 5.7) conditions, but not in the 0 mg/ml condition [ts (29) < -2.9; ps < 0.05]. Immediately
following bout 2, men obtained significantly higher mean nicotine boost in the 18 (M = 8.9; SD
= 12.6) and 36 mg/ml (M = 10.6; SD = 10.0) conditions relative to women who showed
significantly lower mean nicotine boost in the 18 (M = 1.9; SD = 3.0) and 36 mg/ml (M = 2.8;
SD = 5.6) conditions but not in the 0 and 8 mg/ml condition [ts (29) < -3.1; ps <.05].
The Effect of Flavor. To explore whether flavor influenced nicotine boost within each
group (ECIG-experienced or -naïve) the same analyses (i.e., mixed ANOVAs with flavor as the
between-subject factor) were conducted using nicotine boost data. Significant condition by time
interactions were observed for ECIG-experienced individuals [F (27, 837) = 11.8, p <.001] and
ECIG-naïve individuals [F (27,783) = 4.1, p <.001], but no significant interactions or main
effects involving flavor (menthol or tobacco) were observed for nicotine boost for either group.
Given that the between-subject variable of interest (flavor) was not involved in any significant
interactions or main effects further post hoc testing was not conducted.
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Puff Topography
The Effect of Abstinence Status. Prior to conducting the main analyses, topography
data were analyzed to explore whether abstinence status influenced puff topography variables of
interest (i.e., puff duration, volume, flow rate, puff number, and IPI). Puff topography data were
analyzed using mixed ANOVAs with abstinence status as the between-subject factor for ECIGexperienced and -naïve individuals.
For ECIG-experienced and -naïve individuals, no significant interactions or significant
main effects involving abstinence status were observed for any topography variable. Importantly,
the absence of significant main effects or interactions involving abstinence status among ECIGexperienced and -naïve individuals suggests that puff topography did not differ between
abstinent and non-abstinent individuals in either group. Thus, the final topography analyses
presented below will include abstinent and non-abstinent participants for each group.
Puff Topography. Using data from all participants (abstinent and non-abstinent), mixed
ANOVAs were conducted to compare each of the puffing parameters of interest: puff duration,
volume and flow rate among ECIG-experienced and -naïve individuals. Additional mixed
ANOVAs were conducted to analyze the puffing variables that were experimentally controlled in
this study: puff number (10) and IPI (30 s). As mentioned previously, IPI is defined here as the
time between the onset of one puff and the onset of a subsequent puff (as seen in Vansickel et al.,
2010, Farsalinos et al., 2014; Spindle et al., 2015).
Mean (SD) puffing parameters for ECIG-experienced and -naïve individuals are
displayed in Table 5. Significant time by group interactions were observed for puff duration
[F (3, 186) = 5.417, p <.05], puff volume [F (3, 186) = 1.23, p <.05] and flow rate [F (1, 62) =
4.42, p <.05]. No significant interactions for puff number or IPI were observed. Significant main

56

effects of group were observed for puff duration [F (1, 62) = 28.28, p < .001] and puff volume [F
(1, 62) = 8.7, p <.01]. For IPI, a significant main effect of time [F (1, 62) = 8.0, p <.05] was
observed. No significant main effects were observed for flow rate or puff number.
Puff Duration. For puff duration, in bout 1, ECIG-experienced individuals took
significantly longer puffs in the 0 mg/ml relative to the 36 mg/ml condition (Tukey’s HSD, p <
.05). No other differences in puff duration were observed across conditions. For puff duration, in
bout 2, ECIG-experienced individuals took significantly longer puffs in the 0 relative to the 36
mg/ml condition and in the 8 relative to the 36 mg/ml conditions. No differences in puff duration
were observed across bouts in ECIG-experienced individuals.
For puff duration, in bout 1, ECIG-naive individuals took significantly longer puffs in the
0, 8 and 18 mg/ml conditions relative to the 36 mg/ml condition (Tukey’s HSD, p < .05). Also,
during bout 1, ECIG-naïve individuals took significantly longer puffs in the 0 relative to the 18
mg/ml condition (Tukey’s HSD, p < .05). During bout 2, ECIG-naïve individuals took
significantly shorter puffs in the 8, 18, and 36 mg/ml conditions relative to the 0 mg/ml
condition. ECIG-naïve individuals took longer puffs in the 0, 8 and 18 mg/ml conditions relative
to the 36 mg/ml condition.
Across groups, for puff duration, planned contrasts revealed significant between group
(ECIG-experienced versus -naïve) differences in each condition and for each ECIG-use bout,
indicating that ECIG-experienced individuals took significantly longer puffs relative to ECIGnaïve individuals when using the 0, 8, 18, and 36 mg/ml liquid nicotine concentration [ts (62) >
3.3, ps < .05].
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Table 5.
Mean (SD) Puff Topography by Liquid Nicotine Concentration and Group for Bouts 1 and 2
Liquid Nicotine Concentration (mg/ml)
Bout 1
0

Bout 2

8

18

36

5.9*+
(2.4)

5.7+
(2.2)

5.0+
(1.9)

4.7+
(3.9)

3.3*
(1.7)

3.0*
(1.5)

2.8*
(1.3)

ECIG-Experienced

175.7*+
(149.7)

181.0*+#
(139.6)

ECIG-Naive

100.0*#
(64.8)

ECIG-Experienced

ECIG-Naïve

0

8

18

36

6.2*+
(2.5)

6.4*+
(2.3)

5.8+
(3.4)

5.1+
(4.6)

2.2
(0.8)

3.6*
(2.1)

3.1*
(1.6)

2.9*
(1.4)

2.3
(1.0)

127.0+
(80.8)

123.3
(168.1)

206.0*+
(202.9)

217.8*+
(177.3)

137.4
(87.6)

123.7
(150.0)

101.5*#
(66.6)

86.5*#
(59.4)

68.3
(64.1)

120.7*
(76.6)

114.1*
(74.1)

97.9*
(67.9)

69.8
(63.9)

31.1
(24.9)

29.8
(16.7)

24.2
(11.0)

26.6
(21.3)

30.9
(20.6)

31.1
(18.2)

23.8+
(10.8)

27.4
(21.1)

32.5
(21.7)

34.1
(18.9)

29.8
(17.9)

31.2
(28.8)

36.4
(22.7)

36.7*
(20.0)

34.6
(22.6)

30.7
(25.4)

ECIG-Experienced

10.1
(0.2)

10.1
(0.4)

10.2
(0.4)

10.1
(0.3)

10.0
(0.3)

10.0
(0.2)

10.0
(0.3)

10.0
(0.2)

ECIG-Naïve

10.0
(0.2)

10.1
(0.2)

10.0
(0.0)

10.1
(0.3)

10.1
(0.3)

10.0
(0.3)

10.0
(0.2)

10.0
(0.2)

ECIG-Experienced

30.0
(0.5)

30.0
(1.2)

29.8
(1.2)

29.8
(0.8)

30.1
(1.1)

30.3
(0.7)

30.1
(1.1)

30.0
(1.0)

ECIG-Naïve

30.0
(1.1)

30.0
(0.7)

30.4
(2.7)

29.7
(1.4)

30.0
(0.9)

30.0
(1.3)

30.1
(0.6)

30.1
(0.8)

Puff Duration (s)
ECIG-Experienced

ECIG-Naive
Volume (ml)

Flow Rate (ml/s)

Puff Number

IPI (s)
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Mean (SD) puff parameters for ECIG-experienced (N = 33) and ECIG-naïve individuals (N =
31) for bouts 1 and 2. Note that puff number (10) and IPI (30 s) were controlled experimentally
(see method). Asterisks (*) indicate significant differences from the 36 mg/ml condition at that
bout and pound symbols (#) indicate across bout differences for that condition and group
(Tukeys HSD; ps < .05). Plus signs (+) indicate significant differences between ECIGexperienced and -naïve individuals (using independent-samples t-tests; ps < .05).
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Puff Volume. For puff volume, in bout 1, ECIG-experienced individuals took
significantly larger puffs in the 0 relative to 18 and 36 mg/ml conditions. Also, larger puffs were
taken in the 8 relative to 18 mg/ml and 36 mg/ml conditions. The same pattern was observed for
bout 2. Across bouts, ECIG-experienced individuals took significantly larger puffs in bout 2
relative to bout 1 only in the 8 mg/ml condition.
For puff volume, during bout 1, ECIG-naïve individuals took significantly larger puffs in
the 0 mg/ml condition relative to 18 and 36 mg/ml condition, in the 8 relative to 18 and 36
mg/ml conditions, and in the 18 mg/ml condition relative to the 36 mg/ml condition. The same
pattern was observed during bout 2. Generally, larger puffs were taken when using lower liquid
nicotine concentrations in both ECIG-use bouts. Also, ECIG-naïve individuals took significantly
larger puffs during bout 2 relative to bout 1, in the 0, 8, and 18 mg/ml conditions but not in the
36 mg/ml condition.
Across groups, for puff volume, planned contrasts revealed significant between group
differences during bout 1 in the 0, 8, and 18 mg/ml condition, such that ECIG-experienced
individuals took larger puffs relative to ECIG-naïve individuals [ts (62) > 2.2, ps < .05]. For bout
2, significant between group differences for puff volume were observed in the 0 and 8 mg/ml
conditions such that ECIG-experienced individuals took significantly larger puffs relative to naïve individuals [ts (62) > 3.1, ps < .05].
Flow Rate. Among ECIG-experienced individuals, no significant differences in flow
rate were observed for any condition or across ECIG-use bouts. For ECIG-naïve individuals, no
significant differences in flow rate were observed for bout 1; however, for bout 2, significantly
greater flow rate was observed in the 8 relative to the 36 mg/ml condition. No differences for
flow rate were observed across bouts for ECIG-naïve individuals. Across groups, for flow rate,
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planned contrasts revealed significant between group differences in the 18 mg/ml condition for
bout 2 with ECIG-naïve individuals having greater flow rate, relative to ECIG-experienced
individuals [t (62) = -2.4, p < .05]. No between group differences for flow rate were observed for
any other condition or bout.
Puff Number. Across groups, for puff number, planned contrasts revealed no significant
between group differences for any condition or ECIG-use bout.
IPI. Across groups, for IPI, planned contrasts revealed no significant between group
differences for any condition or ECIG-use bout.
Puff Topography and the Effect of Gender. To explore whether gender influenced
puff topography variables within each group (ECIG-experienced or -naïve) the same analyses
(i.e., mixed ANOVAs with gender as the between-subject factor) were conducted for puff
topography. For ECIG-experienced individuals no significant main effects or interactions
involving gender were observed. For ECIG-naïve individuals a significant condition by gender
interaction [F (3, 87) = 3.3, p <.05] was observed for flow rate but no other significant
interactions involving gender were observed for any other puff topography variables. For puff
duration a significant main effect of gender [F (1, 29) = 9.1, p <.01] was observed. For puff
volume, a significant main effect of gender [F (1, 29) = 10.7, p <.01] was observed. No other
significant main effects of gender were observed for any other topography variables.
Mean (SD) puffing parameters for ECIG-naïve individuals are displayed in Table 6. For
ECIG-naïve individuals, significant gender differences were observed for puff duration for bout
1 and 2 in every condition [ts (29) < -2.2, ps < .05]. Overall, men took significantly longer puffs
relative to women during bout 1 and 2 in every condition.
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Table 6.
Mean (SD) Puff Topography by Liquid Nicotine Concentration for ECIG- naïve Individuals by Gender for Bouts 1 and 2
Liquid Nicotine Concentration (mg/ml)
Bout 1

Bout 2

0

8

18

36

0

8

18

36

Men

3.9 +
(1.7)

3.6 +
(1.4)

3.4 +
(1.3)

2.5 +
(0.8)

4.3 +
(2.4)

3.8 +
(1.6)

3.8 +
(1.4)

2.8 +
(0.9)

Women

2.6
(1.3)

2.1
(1.2)

2.0
(0.9)

1.8
(0.5)

2.7
(1.4)

2.3
(1.1)

2.1
(0.9)

1.8
(0.7)

Men

106.7
(57.1)

130.0 +
(66.0)

111.6 +
(60.3)

87.9 +
(76.6)

133.2
(79.2)

146.2 +
(73.6)

127.4 +
(67.3)

89.3 +
(75.9)

Women

90.9
(75.6)

62.6
(45.7)

51.9
(37.7)

41.2
(24.3)

103.3
(72.3)

69.6
(48.6)

57.1
(44.8)

42.6
(25.8)

Men

28.3
(10.5)

37.1
(19.0)

36.0 +
(19.5)

37.0
(35.5)

31.7
(12.9)

40.1
(20.3)

39.1
(21.1)

35.1
(30.7)

Women

38.4
(30.9)

30.0
(18.9)

21.3
(11.2)

23.2
(12.8)

42.9
(31.2)

32.0
(19.5)

28.4
(24.0)

24.6
(14.6)

Men

10.0
(0.0)

10.0
(0.2)

10.0
(0.0)

10.2
(0.4)

10.0
(0.2)

10.0
(0.2)

10.0
(0.0)

10.0
(0.0)

Women

10.1
(0.3)

10.1
(0.3)

10.0
(0.0)

10.0
(0.0)

10.0
(0.0)

10.0
(0.0)

10.1
(0.3)

10.0
(0.0)

Men

30.0
(0.4)

30.0
(1.2)

30.1
(1.2)

29.7
(0.5)

30.1
(0.9)

30.3
(0.6)

30.1
(1.1)

30.0
(1.0)

Women

30.0
(1.1)

30.0
(0.7)

30.0
(2.7)

29.8
(1.4)

30.0
(0.9)

30.0
(1.3)

30.1
(0.6)

30.1
(0.8)

Puff Duration (s)

Volume (ml)

Flow Rate (ml/s)

Puff Number

IPI (s)
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Mean (SD) puff parameters for ECIG-naïve men (N = 18) and women (N = 15) for bouts 1 and
2. Note, IPI (30 s) and puff number (10) were controlled experimentally (see method) and data
are included here to demonstrate that control. Plus signs (+) indicate significant differences
between men and women (using independent-samples t-tests; ps < .05).
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For puff volume, significant gender differences were observed for bouts 1 and 2 in the 8, 18, and
36 mg/ml conditions, such that men took significantly larger puffs relative to women in all
conditions except 0 mg/ml [ts (29) < -2.1, ps < .05]. Also, significant between group differences
were observed for flow rate in the 18 mg/ml condition in bout 1 such that men took significantly
faster puffs relative to women in the 18 mg/ml condition only [ts (29) < -1.2, ps < .05]. No other
significant between group differences were observed for gender.
Puff Topography and the Effect of Flavor. To explore whether flavor (menthol or
tobacco) influenced puff topography variables within each group (ECIG-experienced or -naïve)
the same analyses (i.e., mixed ANOVAs with flavor as the between-subject factor) were
conducted for puff topography. For ECIG-experienced and -naive individuals, no significant
interactions or main effects involving flavor were observed.
Heart Rate
Heart Rate and the Effect of Abstinence Status. To evaluate the effects of abstinence
status on HR, mixed ANOVAs with abstinence as the between-subject factor were conducted for
each group (ECIG-experienced and -naïve). For ECIG-experienced individuals, a significant
three way condition by time by abstinence status interaction was observed [F (6, 186) = 38.1, p
<.01]. Also, significant condition by time [F (6, 186) = 11.5, p <.001] and significant time by
abstinence status interactions [F (2, 62) = 4.6, p <.05] were observed. Among ECIG-experienced
individuals, relative to baseline, abstinent individuals exhibited significant increases in HR
during bout 1 and 2 in all active liquid nicotine conditions (8, 18, and 36 mg/ml) but not in
placebo (0 mg/ml). Non-abstinent individuals had significant increases in HR during bout 1 in all
active nicotine conditions but not 0 mg/ml. Non-abstinent individuals did not have significant
HR increases during bout 2 in any condition. Among ECIG-naïve individuals, a significant
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condition by time interaction was observed [F (6,174) = 4.8, p <.001] but no interactions or main
effects involving abstinence status were observed.
To explore whether abstinence status influenced HR differences observed during ECIG
use, or whether they occurred due to baseline differences (as seen above with plasma nicotine
concentration), the same analyses (i.e., mixed ANOVAs) were conducted using HR difference
scores (i.e., change scores from baseline for each individual in each condition). When using
difference scores for HR, the interactions and main effects involving abstinence status, reported
above, remained significant. Because abstinence status appears to influence HR despite the
correction for baseline differences, abstinence status is believed to have influenced HR during
the course of this study. Thus, final analyses were conducted using only abstinent participants
and using raw HR data (rather than difference scores). For ECIG-naïve individuals, abstinence
status did not appear to influence HR, however, in order to maintain consistency across groups,
HR data for ECIG-naïve individuals was analyzed using only abstinent participants.
Heart Rate Analyses Using Raw Data for Abstinent ECIG-Experienced and -Naïve
Individuals. Among ECIG-experienced individuals, HR differs as a function of abstinence status
despite correction for baseline differences in HR. As such, raw HR data were analyzed using
only data from those participants that had abstained in both groups: ECIG-experienced (N = 18)
and -naïve (N = 21). Using raw HR data, a significant condition by time interaction was observed
[F (6, 222) = 17.8, p < .001]. Also, a significant time by group interaction [F (2, 74) = 5.3, p <
.05] was observed. Significant main effects of condition [F (3, 111) = 3.1, p < .05] and time [F
(2, 74) = 73.2, p < .001] were observed. Figure 5 depicts mean HR, at baseline, during bout 1
and bout 2, by condition, for abstinent ECIG-experienced and -naïve individuals.
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For ECIG-experienced individuals during bout 1, mean (SD) HR increased significantly
from baseline in the 8 (M = 72.9; SD = 7.7), 18 (M = 77.7; SD = 8.1), and 36 (M = 77.4; SD =
9.2) mg/ml conditions, but not in the 0 mg/ml condition (Tukey’s HSD, ps < .05; see Figure 5).
During bout 2, mean (SD) HR increased significantly from baseline in the 8 (M = 69.5; SD =
8.1), 18 (M = 73.3; SD = 10.0), and 36 (M = 73.0; SD = 10.6) mg/ml conditions but not in the 0
mg/ml condition.
For ECIG-naïve individuals during bout 1, mean (SD) HR increased significantly from
baseline in the 8 (M = 73.0; SD = 7.3), 18 (M = 74.3; SD = 7.6), and 36 (M = 76.7; SD = 8.2)
mg/ml conditions, but not in the 0 mg/ml condition (Tukey’s HSD, p < .05; see Figure 5). During
bout 2, mean (SD) HR increased significantly in the 18 mg/ml (M = 70.0; SD = 7.2) and the
36mg/ml (M = 72.4; SD = 8.4) conditions, but not in the 0 or 8 mg/ml conditions. Across
groups, for HR, planned contrasts revealed no significant between group (ECIG-experienced
versus -naïve) differences for any condition or ECIG-use bout.
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Heart Rate

bpm

80

ECIG-Experienced (N =18)

ECIG-Naive (N = 21)

80

75

75

70

70

65

65

60

60

55
BL

Bout 1

Bout 2

36 mg/ml
18 mg/ml
8 mg/ml
0 mg/ml
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Heart Rate Relative to Baseline

Figure 5. Mean (± SEM) for HR across conditions for abstinent ECIG-experienced (N = 18) and
-naïve (N = 21) individuals. Prior to analysis, HR data were averaged to produce a single value
for baseline and the five minutes during each of the two ECIG-use bouts (i.e., bout 1 and bout 2).
Filled symbols indicate a significant difference from baseline; no significant between group
differences were observed.
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Heart Rate and the Effect of Gender. To explore whether gender influenced HR within
each group (ECIG-experienced or -naïve) the same analyses (i.e., mixed ANOVAs with gender
as the between-subject factor) were conducted using raw data and only abstinent individuals. For
ECIG-experienced individuals, a significant condition by time interaction was observed [F (6,
96) = 11.8, p <.01] but no significant main effects or interactions involving gender were
observed. For ECIG-naïve individuals a significant condition by time interaction [F (6, 114) =
7.2, p <.01] and a main effect of gender [F (1, 19) = 5.9, p <.05] were observed.
For ECIG-naïve individuals, across gender, planned contrasts revealed significant
between group differences in HR in the 36 mg/ml condition at baseline and during bout 1 [ts (19)
< -2.3, ps < .05]. Mean (SD) HR was significantly higher for women at baseline (M = 72.5; SD =
5.0), during bout 1 (M = 81.7; SD = 7.1) and during bout 2 (M = 76.5; SD = 8.3) relative to men
who had significantly lower HR at baseline (M = 63.6; SD = 5.5), during bout 1 (M = 72.1; SD =
6.2) and bout 2 (M = 68.7; SD = 6.9).
Heart Rate Evaluation of Flavor. To explore whether flavor influenced HR within each
group (ECIG-experienced or -naïve) the same analyses (i.e., mixed ANOVAs with flavor as the
between-subject factor) were conducted using HR data and abstinent individuals only.
Significant condition by time interactions were observed for ECIG-experienced individuals [F
(6, 96) = 11.5, p <.01] and for ECIG-naïve individuals [F (6, 114) = 7.2, p <.001] but no
significant interactions or significant main effects involving flavor were observed for either
group. Given that the between-subject variable of interest (flavor) was not involved in any
significant interactions or main effects further post hoc testing was not conducted.
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Discussion
Overview
ECIGs are a class of products that, until recently, were unregulated in the U.S. ECIG
device features, liquid characteristics, and user behavior often vary considerably, making the
understanding of the acute effects of ECIGs difficult. Until this report, no published studies have
evaluated systematically the effects of various liquid nicotine concentrations, user experience,
and puff topography on ECIG-associated nicotine delivery.
Results from this study, in which liquid nicotine concentration and user experience were
varied while other factors (e.g., battery voltage, heater resistance, liquid PG:VG ratio) were held
constant, indicate that liquid nicotine concentration influences nicotine delivery (as indexed by
plasma nicotine concentration), that ECIG nicotine delivery is physiologically active, and that
the amount of nicotine delivered depends upon user puff topography. Specifically, ECIGexperienced individuals obtained higher mean nicotine boost relative to ECIG-naïve individuals
and this difference may be due to the longer and larger puffs taken by ECIG-experienced
individuals. Also, puff topography differed based on liquid nicotine concentration such that
longer and larger puffs are taken in the lower nicotine concentrations relative to the higher liquid
nicotine concentrations. In addition to these results, the study also reveals that some participants
likely did not comply with protocol-mandated nicotine abstinence, and this non-compliance has
important implications for future clinical laboratory research addressing ECIG effects. Taken
together, results from this study are important for ECIG regulation because they reveal how
ECIG nicotine delivery might be controlled.
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ECIG Nicotine Delivery
ECIG nicotine delivery is related directly to liquid nicotine concentration (when all other
factors are controlled), is physiologically active, and depends upon user puff topography.
The relationship between ECIG liquid nicotine concentration and user nicotine boost is
illustrated in Figure 3 which demonstrates an increase in mean nicotine boost with increase of
liquid nicotine concentration for each of the 2 ECIG-use bouts in ECIG-experienced and -naïve
individuals. While between group differences in nicotine boost are apparent (as seen in Figures 3
and 4), the direct relationship between liquid nicotine concentration and plasma nicotine
concentration can be more clearly seen when collapsed across group. Indeed, when the mean
peak nicotine boost data are collapsed across groups, the effect of liquid nicotine concentration is
clear: after bout 1, collapsed across group, a mean (SD) peak nicotine boost of 0.9 ng/ml (1.7)
was observed in the 0 mg/ml condition, a mean nicotine boost of 6.3 ng/ml (4.8) was observed in
the 8 mg/ml condition, a mean nicotine boost of 10.6 ng/ml (11.6) was observed in the 18 mg/ml
condition, and a mean nicotine boost of 14.0 ng/ml (14.2) was observed in the 36 mg/ml
condition. Immediately following bout 2, collapsed across group, a mean (SD) peak nicotine
boost of 0.6 ng/ml (3.3) was observed in the 0 mg/ml condition, a mean peak nicotine boost of
6.8 ng/ml (7.0) was observed in the 8 mg/ml condition, a mean peak nicotine boost of 9.7 ng/ml
(11.4) was observed in the 18 mg/ml condition, and a mean peak nicotine boost of 13.0 ng/ml
(11.8) was observed in the 36 mg/ml condition. Thus, for both bouts and collapsed across
groups, mean peak nicotine boost increased with the increase in liquid nicotine concentration
using the experimental methods described here.
Results from this study indicate that the ECIG-nicotine delivery was physiologically
active, as indexed by heart rate increases that were observed where nicotine was delivered
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reliably (as indexed by plasma nicotine boost). To highlight this point, mean peak nicotine boost
and mean HR data from abstinent ECIG-experienced individuals only, are shown together in
Figure 6. Immediately after bout 1, abstinent ECIG-experienced individuals obtained mean (SD)
peak nicotine boost of 0.0 ng/ml (0.2) in the 0 mg/ml condition, 6.8 ng/ml (6.2) in the 8 mg/ml
condition, 11.1 ng/ml (8.3) in the 18 mg/ml condition, and 14.8 ng/ml (14.8) in the 36 mg/ml
condition. A similar trend was observed in HR during bout 1 such that abstinent ECIGexperienced individuals mean (SD) HR was 72.6 beats/minute (1.2) in the 0 mg/ml condition,
72.9 beats/minute (1.3) in the 8 mg/ml condition, 77.7 (1.4) beats/minute in the 18 mg/ml
condition, and 77.4 beats/minute (1.6) in the 36 mg/ml condition. Mean peak nicotine boost was
significantly higher in the 8, 18, and 36 mg/ml conditions relative to 0 mg/ml (Tukey’s HSD, p <
.05). HR increases during bout 1 were significantly higher in the 18 and 36 mg/ml conditions
relative to 0 mg/ml, but not in the 8 mg/ml condition. Overall, results of the present study
demonstrated that ECIG-experienced and -naïve individuals were exposed to physiologically
active nicotine concentrations (as indexed by observed increases in heart rate) immediately
following product administration, especially at higher liquid nicotine concentrations.
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Figure 6. Mean (± SEM) peak nicotine boost and HR across conditions (liquid nicotine
concentration) for abstinent ECIG-experienced individuals (N = 18). Right y-axis depicts HR
during bout 1 and left y-axis depicts nicotine boost immediately following bout 1. Filled symbols
indicate significant difference from 0 mg/ml at that liquid nicotine concentration (Tukey’s HSD;
ps < .05).
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Similar to previous reports (Farsalinos et al., 2015) ECIG user nicotine delivery differed
significantly across ECIG-experienced and -naïve individuals in this study. Despite controlling
for several characteristics that may influence nicotine delivery (e.g., battery voltage, liquid
PG:VG ratio, puff number) ECIG-experienced individuals obtained higher nicotine boost relative
to ECIG-naïve individuals in all active nicotine conditions (see Figure 3 and Figure 4). The
variability in ECIG-associated nicotine delivery across ECIG-experienced and -naïve individuals
may be explained by differences in user puff topography. Analytical laboratory studies have
demonstrated how differences in puff topography may influence ECIG-associated nicotine yield.
For example, puff duration influences nicotine yield such that longer duration puffs result in
greater nicotine yield (Talih et al., 2015). In fact, ECIG-experienced individuals take longer
puffs (approximately 4 s, on average) while ECIG-naïve individuals, who are also tobacco
cigarette smokers, take shorter puffs (approximately 2 s, on average; Hua et al., 2013; Farsalinos
et al., 2013). Consistent with these data, the present study demonstrated that ECIG-experienced
and -naïve individuals differ significantly on several puffing parameters. As displayed in Table
5, ECIG-experienced individuals took significantly longer, larger puffs relative to ECIG-naïve
individuals. Thus, the significantly higher mean nicotine boost observed in ECIG-experienced
individuals may be explained by the differences in puff topography across groups. For example,
in the 18 mg/ml condition, immediately following bout 1, in ECIG-experienced individuals, a
mean (SD) peak nicotine boost of 13.0 ng/ml (13.2) was observed while, in ECIG-naïve
individuals a mean peak nicotine boost of 6.2 ng/ml (10.2) was observed. In the 18 mg/ml
condition, during bout 1, ECIG-experienced individuals took mean (SD) puffs of 5.0 s (1.9)
duration and ECIG-naïve individuals took mean puffs of 2.8 s (1.3) duration. Similar between
group differences in mean puff duration and mean peak nicotine boost were seen across all active
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liquid nicotine concentrations. As such, results from the present study suggest strongly that
ECIG-nicotine delivery is related directly to user puff topography when other relevant factors are
held constant.
The present study also demonstrated that ECIG user puff topography differs based on the
liquid nicotine concentration used (see Table 5). For example, regardless of group (ECIGexperienced or -naïve) longer and larger puffs were taken in the lower nicotine concentrations
relative to the higher liquid nicotine concentrations. During bout 1, collapsed across group, mean
(SD) puff duration was 4.7 s (2.4) in the 0 mg/ml condition, 4.4 s (4.0) in the 8 mg/ml condition,
4.0 s (3.7) in the 18 mg/ml condition, and 3.5 s (2.8) in the 36 mg/ml condition. For puff volume,
during bout 1, collapsed across group, mean (SD) puff volume was 140.1 ml/s (121.8) in the 0
mg/ml condition, 142.5 ml/s (116.7) in the 8 mg/ml condition, 107.4 ml/s (73.5) in the 18 mg/ml
condition, and 96.7 ml/s (130.7) in the 36 mg/ml condition. These findings suggest that
regardless of experience with ECIGs, puffing behavior may differ depending on liquid nicotine
concentration.
The nicotine delivery findings of the present study have several implications. First, this is
the first report to demonstrate systematically a direct relationship between liquid nicotine
concentration and plasma nicotine concentration. As such, liquid nicotine concentration should
be considered one of the several factors that influence ECIG-related nicotine delivery. Second,
the mean nicotine boost observed in participants in this study were accompanied by increases in
HR suggesting that the nicotine delivered from an ECIG is physiologically active, and the
physiological activity of this psychomotor stimulant drug may contribute to maintenance or
initiation of nicotine dependence with continued use. Third, the between group differences in
puff topography observed in this study are consistent with previous reports (Farsalinos et al.,
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2015; Spindle et al., 2015) and may explain the observed differences in nicotine delivery
between ECIG-experienced and -naïve individuals. Understanding puff topography differences
between ECIG-experienced and -naïve individuals may help in understanding why previous
reports of ECIG-related nicotine delivery varied so widely. For example, early evaluations of
ECIG-associated nicotine delivery demonstrated the following: after 10 puffs, ECIG-naïve
cigarette smokers were unable to obtain measureable amounts of nicotine from an ECIG
(Vansickel et al., 2010), after 10 puffs of a tank-based ECIG, ECIG-experienced individuals
were able to obtain some nicotine (M = 6.6 ng/ml; Farsalinos et al., 2014), and that when using
their own device/liquid ad libitum, some ECIG-experienced individuals obtained plasma nicotine
concentrations that exceeded those observed in tobacco cigarette smokers (M = 35 ng/ml;
Spindle, 2015). The variability in ECIG nicotine delivery across these reports may be explained
by the differences in ECIG experience of the population sampled (i.e., ECIG-naïve in Vansickel
et al., 2010; ECIG-experienced in Spindle et al., 2015) and the related differences in puff
topography of those populations. However, the variability in the devices and liquids used in
previous studies makes the examination of the specific factors that may influence nicotine
delivery (i.e., device characteristics, liquid characteristics, puff topography) difficult. Overall,
generalizations regarding ECIG nicotine delivery across devices that vary in power and other
design features may be challenging, especially if puff topography and liquid nicotine
concentration are not taken into account.
Finally, ECIG-experienced and -naïve participants in this study may have altered the
duration and volume of their puffs when using certain liquid nicotine concentrations and this
behavioral alteration may be a result of two different mechanisms. First, perhaps the larger and
longer puffs observed in the lower liquid nicotine concentrations relative to the higher liquid
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nicotine concentrations may be an attempt, by users, to obtain higher nicotine levels by adjusting
puff topography. Second, the higher liquid nicotine concentrations may be perceived as more
“harsh” and thus more difficult to inhale. However, further examinations are required in order to
understand the mechanism behind the larger and longer puffs observed at lower liquid nicotine
concentrations.
Puff Topography
In the present study, mean ECIG nicotine boost varied significantly across ECIGexperienced and -naïve individuals, perhaps due to the longer and larger puffs taken by ECIGexperienced individuals. Consistent with the findings of the present study, previous reports
indicate that when using an ECIG, ECIG-experienced individuals take longer duration puffs
(approximately 4 s, on average) while ECIG-naïve individuals, who are also tobacco cigarette
smokers, take shorter puffs (approximately 2 s, on average; Hua et al., 2013; Farsalinos et al.,
2013). Taken together, the between group differences observed in nicotine boost and puff
topography indicate that the ability to obtain nicotine from an ECIG may be a learned behavior
that requires practice. One possible explanation for the differences observed in puffing behavior
between ECIG-experienced and -naïve individuals is that ECIG-experienced individuals, over
time, have learned that longer duration puffs result in greater nicotine delivery. Indeed, data from
analytical laboratory studies corroborate that longer-duration puffs result in greater nicotine yield
(Talih et al., 2015). Specifically, during a longer duration puff, the heater coil of an ECIG is
activated for a longer period of time resulting in a larger proportion of the puffing time spent in a
higher-temperature phase (Talih et al., 2015). When puffing occurs in a higher temperature phase
the result is higher nicotine evaporation and greater nicotine yield. Thus, longer duration puffs
lead to greater nicotine yield and potentially greater nicotine delivery to the user. Perhaps, over
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time, those ECIG users that took longer duration puffs from an ECIG were reinforced by
subsequent nicotine boost that may have resulted in even longer duration puffs in the future.
ECIG-naïve tobacco cigarette smokers are one group of individuals who may be motivated to
switch completely from combustible cigarettes to ECIGs and these cigarette smokers may seek
an ECIG nicotine delivery profile comparable to a tobacco cigarette (e.g., nicotine boost of 16.8
ng/ml immediately after the 10th puff of a 10-puff bout; Vansickel et al., 2010). For those ECIGnaïve smokers attempting to obtain cigarette-like nicotine boost from an ECIG, altering their
puffing behavior in a manner that is associated with higher nicotine delivery (i.e., longer duration
puffs) may assist in achieving higher nicotine delivery. As such, if ECIGs are to be used in place
of tobacco cigarettes, and if that replacement depends upon the ECIG matching the nicotine
delivery of a tobacco cigarette, then there is a potential need for more detailed instructions
regarding proper puffing techniques when using ECIGs in order for ECIG-naïve cigarette
smokers to obtain cigarette-like nicotine boosts from an ECIG from their very first 10 puffs.
To date, one study has demonstrated that ECIG-naïve cigarette smokers appear to adjust
their puffing parameters during the first week of a two-week ECIG use period (Lee, Gawron, &
Goniewicz, 2015). Specifically, ECIG-naïve cigarette smokers modified their puffing behavior
after switching from tobacco cigarettes to ECIGs by taking longer and slower puffs. For
example, during baseline ECIG use, mean (SEM) puff duration of smokers was 2.2 s (0.1), after
one week puff duration was 3.1 s (0.3), and after two weeks puff duration was 2.9 s (0.2; Lee et
al., 2015). Puff flow rate also changed from baseline with participants flow rate decreasing from
30.6 ml/s (2.3) to 25.1 (1.8) ml/s after one week, down to 24.8 ml/s (1.9) after week two. The
observed changes in puffing behavior may be evidence that perhaps engaging in certain puffing
behaviors is more rewarding, such as when more nicotine is delivered to the user when taking
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certain puffs. Changes in puffing behavior after a two week ECIG use period indicate that after
two weeks of ad libitum ECIG use, ECIG-naïve tobacco cigarette smokers alter their puffing
behavior significantly such that puff durations are longer. These results support the idea that,
over time, ECIG-naïve individuals may learn how to puff an ECIG in a manner that is consistent
with increases nicotine yield and nicotine delivery (i.e., longer duration puffs; Talih et al., 2015).
In sum, the variability in mean nicotine boost among ECIG-experienced and -naïve
individuals may be explained by differences in puff topography. In general, ECIG-experienced
individuals take longer and larger puffs relative to ECIG-naïve individuals, which may explain
their ability to obtain more nicotine from an ECIG. Perhaps ECIG-experienced individuals have
learned, over time that longer duration puffs result in greater nicotine delivery. Perhaps the
puffing behavior required to obtain nicotine from an ECIG is a learned behavior that requires
practice. Thus, for ECIG-naïve tobacco cigarette smokers looking to achieve cigarette-like
nicotine delivery from an ECIG (e.g., nicotine boost of 16.8 ng/ml; Vansickel et al., 2010),
altering puffing behavior in a manner that is consistent with higher nicotine yield and delivery
(i.e., longer duration puffs; Talih et al., 2015) may be one way to increase ECIG-associated
nicotine delivery.
ECIG Nicotine Delivery Profile Can Exceed That of Combustible Cigarettes
As in previous reports (e.g., Spindle et al., 2016), several ECIG-experienced individuals
across each of the active liquid nicotine concentrations in the present study were able to obtain a
nicotine boost that exceeds what is typically observed in tobacco cigarette smokers (e.g.,16.8
ng/ml mean nicotine boost; Vansickel et al., 2010) under similar puffing conditions (i.e., 10
puffs; 30 s IPI). Specifically, following the first 10-puff ECIG use bout, three ECIG-experienced
individuals exceeded a cigarette-like nicotine boost when using the 8 mg/ml liquid (M = 25.2
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ng/ml; SD = 10.1), nine exceeded cigarette-like nicotine boost when using the 18 mg/ml liquid
(M = 30.3 ng/ml; SD = 11.1) and 13 exceeded cigarette-like boost when using the 36 mg/ml
liquid (M = 35.5 ng/ml; SD = 14.7). Conversely, 30 obtained below cigarette-like nicotine boost
when using the 8 mg/ml liquid (M = 6.5 ng/ml; SD = 5.3), 24 obtained below cigarette-like
nicotine boost when using the 18 mg/ml liquid (M = 6.4 ng/ml; SD = 6.0), and 20 obtained
below cigarette-like nicotine boost when using the 36 mg/ml liquid (M = 6.6 ng/ml; SD = 4.7).
Among ECIG-naïve individuals, three obtained cigarette-like nicotine boost when using
the 18 mg/ml liquid (M = 32.2 ng/ml; SD = 14.3) and three obtained cigarette-like boost when
using the 36 mg/ml liquid (M = 22.3 ng/ml; SD = 3.7). Conversely, 31 obtained below cigarettelike nicotine boost when using 0 mg/ml liquid (M = 0.0 ng/ml; SD = 1.5), 31 obtained below
cigarette-like nicotine boost when using the 8 mg/ml liquid (M = 3.6 ng/ml; SD = 3.8), 28
obtained below cigarette-like nicotine boost when using the 18 mg/ml liquid (M = 3.4 ng/ml; SD
= 4.6), and 28 obtained below cigarette-like nicotine boost when using the 36 mg/ml liquid (M =
5.2 ng/ml; SD = 5.1).
These findings have several important implications. First, under certain conditions,
ECIG-experienced and -naïve individuals are able to achieve and sometimes exceed the nicotine
boost observed after 10 puffs of a tobacco cigarette (i.e., 16.8 ng/ml; Vansickel et al., 2010).
Second, as seen in previous studies (Dawkins & Corcoran, 2013; Farsalinos et al., 2014; Spindle
et al., 2015; Vansickel & Eissenberg, 2013), nicotine delivery varied considerably among ECIGexperienced individuals in this study. For example, some ECIG-experienced individuals, in the
present study, were able to achieve much higher nicotine boost relative to the nicotine boost seen
after 10 puffs of a tobacco cigarette (e.g., 66.18 ng/ml after 10 puffs of a 3.3 V “eGo” battery
using 36 mg/ml liquid nicotine concentration), while others only were able to obtain minimal
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nicotine boost. Given that several factors such as device characteristics (i.e., battery voltage,
heater resistance) and liquid characteristics (i.e., liquid solvents) were held constant in this study,
they likely did not contribute to the variability in ECIG-associated nicotine delivery. Instead, one
possible explanation for the variability in nicotine delivery is individual variability in puff
topography. As such, puff topography should be considered a highly important variable in ECIGassociated nicotine delivery.
Measurement of Abstinence
The present study also reveals that some participants likely did not comply with protocolmandated nicotine abstinence, and this non-compliance has important implications for future
clinical laboratory research addressing the acute effects of ECIGs and other non-combustible
tobacco products. As in previous studies of tobacco and nicotine containing products (Dawkins
et al., 2013; Spindle et al., 2015; Vansickel et al., 2010; Kotlyar, et al., 2007; Perkins, Grobe, Weiss,
Fonte, & Caggiula, 1996), ≥ 12 hours nicotine/ tobacco abstinence was required prior to each

laboratory session for ECIG-experienced individuals and ECIG-naïve smokers. Nicotine/tobacco
abstinence is required to assess nicotine delivery and the examination of abstinence symptom
suppression associated with using nicotine/tobacco (e.g., Dawkins et al., 2016; Spindle et al.,
2015; Dawkins & Corcoran, 2014; Kotlyar, et al., 2007; Perkins et al., 1996).Consistent with

previous reports, in this study, short-term abstinence from combustible products, such as tobacco
cigarettes, was evaluated with a test of expired air CO concentration. However, under normal
conditions, ECIGs are not combustible and do not produce CO. Therefore, ECIG-experienced
individuals had abstinence verified retrospectively (using a criterion of plasma nicotine
concentration < 5 ng/ml; as in Spindle et al., 2016) and ultimately, 18 of the 33 ECIGexperienced individuals and 21 of the 31 ECIG-naïve tobacco cigarette smokers were considered
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to have abstained from nicotine prior to each of the four sessions. Thus, this study highlights a
challenge with studying nicotine/tobacco use when short-term abstinence from non-combustible
tobacco products (i.e., ECIGs) cannot be verified immediately (i.e., prior to the start of the study
session). Given that some outcome measures such as HR in this study and, potentially, subjective
effect measures of nicotine/tobacco abstinence may be affected by nicotine abstinence,
measuring short-term ECIG abstinence will continue to be challenging in future research until an
immediate, reliable, and cost-effective method for verifying abstinence from non-combustible
tobacco products is discovered.
Among those in the study who were ECIG-experienced, almost half were considered to
be non-abstinent during the study. Non-abstinence among study participants who were required
to abstain is informative for several reasons. First, perhaps ECIG-experienced individuals are
aware that ECIGs do not operate via combustion and that CO measurement is not a reliable
measure for ECIG abstinence. If this speculation is correct, measurement of ECIG abstinence
increasingly may be problematic in the clinical laboratory. Second, another possible explanation
for failure to comply with protocol-required nicotine/tobacco abstinence was that participants,
including non-smoking, ECIG-experienced individuals, experienced difficulty when trying to
abstain. This difficulty abstaining is reminiscent of the difficulty cigarette smokers report when
attempting to abstain from nicotine/tobacco (e.g., Hughes & Hatsukami, 1986; Buchhalter,
Acosta, Evans, Breland, & Eissenberg, 2005) and may indicate that ECIG-experienced
individuals in this study were experiencing a similar aversive abstinence syndrome (e.g., Hughes
& Hatsukami, 1986). Because ECIGs have been shown, under some conditions, to deliver
physiologically active nicotine to the user (Spindle et al., 2015; Vansickel & Eissenberg, 2013),
perhaps the same aversive syndrome that is experienced by abstinent tobacco cigarette smokers,
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and that is considered a hallmark of tobacco/nicotine dependence, also may occur in ECIG users,
and may also be an indicator of dependence in this population. Some reports suggest that ECIGassociated nicotine dependence may be less severe than dependence on tobacco cigarettes (Etter
& Eissenberg, 2015; Foulds et al., 2014). Importantly, these reports may have been based on
ECIG-experienced individuals who were using ECIGs that were less effective at delivering
nicotine than those on the market today (e.g., Vansickel et al., 2012; Farsalinos et al., 2015).
More research regarding ECIG-associated nicotine dependence is required to understand why
some ECIG users did not abstain during the course of this study, and to what extent this failure to
abstain is an indicator of nicotine dependence.
Prior to this report, several clinical laboratory studies verified tobacco/nicotine abstinence
in tobacco cigarette smokers using a test of expired air CO (e.g., ≤ 10 ppm; Dawkins et al., 2016;
Vansickel et al., 2010; Mendelson et al., 2008; Breland et al., 2002). However, in the present
study, despite verifying tobacco abstinence (using expired air CO ≤ 10 ppm), 10 of the 31 ECIGnaïve tobacco cigarette smokers were considered to be not abstinent when plasma nicotine
concentration was analyzed retrospectively (using a criterion of plasma nicotine concentration <
5 ng/ml at baseline; as in Spindle et al., 2016). There are two potential explanations for why
combustible tobacco cigarette smokers appeared abstinent (as indexed by having expired air CO
of ≤ 10 ppm) prior to the start of the session, but had baseline plasma nicotine concentrations that
exceeded 5 ng/ml. First, with several non-combustible nicotine delivery products on the market
(i.e., ECIGs, nicotine replacement therapies, smokeless tobacco products), tobacco cigarette
smokers may have used a non-combustible form of nicotine delivery prior to the session in order
to avoid the aversive abstinence syndrome associated with tobacco abstinence (e.g., Hughes &
Hatsukami, 1986). Second, perhaps the expired CO criterion of ≤ 10 ppm may lead some
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individuals who have smoked a combustible tobacco product within 12 hours to be misclassified
as abstinent (Cropsey, Eldridge, Weaver, Villalobos, & Stitzer, 2006). Indeed, recent reports
have demonstrated that perhaps the optimal CO criterion cut off for 24 hour tobacco cigarette
abstinence is either between 3-6 ppm (Cropsey, Elridge, Weaver, Villalobos, & Stitzer, 2006) or
below 5 ppm (Perkins et al., 2012). However, these cut off recommendations are made to
classify between smokers and non-smokers and may be more valuable for cessation studies
rather than studies requiring acute abstinence from tobacco cigarettes. Nonetheless, future
studies may benefit from enforcing a stricter CO criterion cut off for abstinent tobacco cigarette
smokers (e.g., < 5ppm; Perkins et al., 2012). Additionally, for non-combustible tobacco
products, such as ECIGs, no immediate biochemical measures for verifying acute nicotine
abstinence have been discovered. Measuring short-term nicotine abstinence will continue to be
challenging in future nicotine and tobacco research until a fast, reliable, and cost-effective
method for verifying abstinence from non-combustible tobacco products is discovered.
Regulatory Implications
Under the “deeming” statute of The Family Smoking Prevention and Tobacco Control
Act, FDA has begun to regulate the labeling, marketing, and distribution of ECIGs. Regulation
of ECIGs will require an understanding of what these products do, what ingredients they contain,
and the extent to which they will have a positive or negative public health impact. Information
from the present study was intended to evaluate systematically several aspects of ECIGassociated nicotine delivery (i.e., liquid and device characteristics) to inform effective ECIG
regulation. Despite not having the necessary empirical information regarding ECIG-associated
nicotine delivery, some countries are already attempting to regulate ECIG liquids and
components.
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For example, in an attempt to protect individual and public health in Europe, European
Union Directive 2014/40/EU recently limited the liquid nicotine concentration of ECIG liquids
to 20 mg/ml. The rationale behind this regulation was to limit the nicotine delivery from an
ECIG to what is comparable when using a tobacco cigarette (i.e., approximately 16 ng/ml, on
average; Vansickel et al., 2010). However, this regulation failed to account for several variables
that also influence ECIG-associated nicotine delivery. Failure to consider variables other than
liquid nicotine concentration (i.e., device characteristics, liquid solvents such as PG:VG, and
user puff topography) can lead to regulatory decisions that fail to serve their intended purpose.
Indeed, doubling device power can triple the nicotine yield when liquid nicotine concentration is
held constant (Talih et al., 2015). Given that the devices used in the current study were powered
at approximately 7 Watts (i.e., 3.3Volts2/1.5 Ohms = 7.26 Watts), and that devices that can be
powered to 60 Watts are now marketed (e.g., myvaporstore.com), attempts to control nicotine
yield and/or delivery by limiting liquid nicotine concentration alone are unlikely to be effective.
Results from the present study may inform regulators that ECIG nicotine delivery is
directly related to liquid nicotine concentration (when all other factors are controlled). However,
ECIG nicotine delivery is also dependent upon user puff topography and the present study
demonstrated significant between group differences in nicotine delivery based on user
experience (i.e., puff topography). The variability in ECIG-associated nicotine delivery should
serve to inform regulators to be cautious about making regulatory decisions that isolate certain
variables, such as liquid nicotine concentration, when several other important variables also
influence ECIG nicotine delivery. For example, if regulation were to limit ECIGs to highWatt/low nicotine concentration combinations, the nicotine delivery from these device/liquid
combinations may be similar to the nicotine delivery from a low Watt/high nicotine
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concentration combination due to variability in puff topography (Shihadeh & Eissenberg, 2014).
Thus, regulators should consider not only device characteristics and liquid nicotine concentration
but also user behavior when making regulatory decisions regarding ECIGs. One way to consider
user behavior in regulation may be to design ECIG devices that limit user puff duration or puff
number in order to limit the nicotine delivery profile of some device/liquid nicotine
combinations.
Limitations
Several important limitations of the present study should be considered. First, the results
obtained from this study’s directed puffing protocol (10 puffs with 30 s IPI) may differ from
those that might be seen after ad libitum puffing in ECIG-experienced or -naïve individuals.
While there are advantages to controlling some puff topography parameters, such as the ability to
compare across studies and products, future studies seeking to evaluate ECIG nicotine delivery
and puff topography in a more naturalistic manner may use an ad libitum puffing protocol and
vary liquid nicotine concentration.
Another potential limitation of this study involves the absence of a combustible tobacco
cigarette control condition that would have allowed for more direct comparison of “own brand”
topography and nicotine delivery across the puffing parameters used in this study (i.e., 10 puffs
with a 30 s IPI). However, several previous evaluations of nicotine delivery and puff topography
when using a tobacco cigarette have been conducted and data from those studies can be used to
make comparisons with the results from this study (Vansickel et al., 2010, Kleykamp et al.,
2008). Also, because many of the ECIG-experienced individuals in the present study were
former cigarette smokers, ethical concerns arise when planning a study that involves asking
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former cigarette smokers to use a product that is known to be dependence-inducing and lethal
when those individuals no longer use that product.
The use of a single cartomizer type in the present study may be considered a limitation as
the cartomizer used may not be representative of the cartomizers or tanks typically used by
experienced ECIG users. Perhaps the puff topography observed when using the study cartomizer
may not be indicative of the puff topography that may be exhibited if participants (especially
ECIG-experienced individuals) used their preferred tank or cartomizer. However, ECIG device
features and parts (cartomizers and tanks) vary markedly. Selecting a cartomizer that is more
“representative” of what is typically used by those individuals who participated in this study
would be difficult and may have compromised internal validity. Because device features may
influence ECIG-associated nicotine delivery, standardizing the device was intended to eliminate
the potential influence of device characteristics on the outcome measures. Also, the use of a
single cartomizer type ensured accurate topography measurement in this study. Future studies
seeking to evaluate more naturalistic puffing behavior may benefit from using a mouthpiecebased device that can accurately measure puff topography in tank-based ECIGs.
Finally, because this study was not designed to measure the effects of gender or flavor
preference, it may have lacked sensitivity to detect differences related to these factors. Because
puff topography differences between men and women have been observed among tobacco
cigarette smokers (Melikian et al., 2006), future studies may benefit from using a larger sample
sizes to explore potential gender differences in ECIG user puff topography.
Conclusions
This within and between-subject clinical laboratory study evaluated the extent to which
liquid nicotine concentration and puff topography influence plasma nicotine concentration in
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ECIG-experienced and -naïve individuals. Results demonstrated that liquid nicotine
concentration is directly related to plasma nicotine concentration and that ECIGs can deliver
physiologically active nicotine concentrations to ECIG-experienced and ECIG-naïve smokers
following 10 puffs. Generally, ECIG-experienced individuals obtained significantly higher mean
plasma nicotine boost relative to ECIG-naïve smokers and this difference depends upon
differences in user puff topography. Under some conditions, some ECIG-experienced and -naïve
individuals obtained a nicotine boost that was greater than the mean nicotine boost typically
observed after 10 puffs from a tobacco cigarette under similar laboratory conditions. ECIGexperienced individuals took longer and larger puffs relative to ECIG-naïve individuals which
may explain the variability in nicotine boost across groups. Taken together, the results of this
study support that ECIG nicotine delivery can vary based on liquid nicotine concentration and
user experience (i.e., puff topography). Finally, regulators should consider device characteristics
and user behavior as well as liquid nicotine concentration when making regulatory decisions
intended to control ECIG nicotine delivery.
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APPENDIX A
Telephone Screening Form
Introduction: This is a research study about e-cigarettes.
Purpose: To compare the effects of different nicotine doses on behavior and how you feel.
Study Details: If you are eligible for this study, you will be asked to visit our lab on the MCV
campus for four sessions. These sessions will begin at approximately the same time each day,
will take approximately 2.5 hours each, and will be separated by at least 48 hours. We will ask
you to abstain from all tobacco products and e-cigarettes, and all nicotine containing products
(like the gum or patch) for at least 12 hours before each session. When you arrive to the lab for
session, we will ask you to take a simple breath test to make sure that you have complied with
these restrictions. Side effects from tobacco/nicotine abstinence can include irritability, anxiety
and restlessness, excessive hunger, difficulty concentrating, and sleep disturbance. Though
uncomfortable, these feelings are not medically dangerous.
At the beginning of each session, a nurse will insert an IV catheter into your arm that will stay
there for the entire session. This catheter will be used to draw blood periodically (less than 1
tablespoon per sample, 10 samples). We will also monitor your heart rate and blood pressure and
ask you to respond to several questionnaires to measure how you feel before and after using an ecigarette. There is some risk of bruising at the catheter site, and there is a minimal risk of
infection associated with any blood draw.
For each session, we will provide you with an e-cigarette that may contain nicotine or no
nicotine. During the session we will ask you to use this e-cigarette at two separate times.
When you use the e-cigarette, you may notice that it is connected to a computer and that there
are pieces of equipment attached to the e-cigarette. The computer and this equipment are
measuring how you use the e-cigarette (the size and number of the puffs that you take).
Confidentiality: We will not tell anyone the answers that you give us; however, information
from the study and the consent form signed by you may be looked at or copied for research or
legal purposes by the sponsor of the research, or by Virginia Commonwealth University.
Payment: You will receive $75 after completing the first session, $75 after completing the
second session, $150 after completing the third session, and $200 after completing the fourth
session. Thus, the total amount you could earn for the entire study is $500.
“Does this sound like something you want to participate in?”
Document caller’s response by circling either:
No
If yes, continue with the following questions.

Yes

or
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Telephone Screening Questionnaire
Date
Interviewer

_______________
_______________

-------------------------------------------------------------------------------------------------------------Interviewer: “I would like to ask you some questions about yourself and your health status as
well as your use of e-cigarettes, tobacco, alcohol, and other drugs. Completion of these questions
will take approximately 10 minutes of your time. The purpose of these questions is to determine
whether or not you are eligible to participate in the study I just described, in addition to other
studies currently ongoing in our laboratory All of your responses are confidential. You are not
required to answer any question and you may stop this interview at any time. May I begin the
questions?”
Document caller’s response by circling either:
No

Yes

or

If Yes: begin form. If No: thank caller for calling.
How did you hear about us/our studies?

________________________

Personal Information:
1. “What is your first name?”

________________________

2. “What is a phone number at which you can be contacted?”

________________________

4. “If we call and you are not available, may we leave a message?”
Circle Yes or
No
5. “What is your date of birth?”

________________________

6. “What is your height?”

__________ (feet and inches)

7. “What is your weight?”

__________ (pounds)

8. “Which identifier best describes you?”
9. “Did you graduate high school?”

Male
Circle Yes

or Female
or

No

If Yes: Skip the next question.
10. “Did you obtain your GED?”:
Circle Yes
or
No
-----------------------------------------------------------------------------------------------------------General health status:
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11. “Do you have any chronic health concerns or problems?”

Circle

Yes

or

No

If Yes: “Please describe the concern or problem”:
12. “Are you under a doctor’s care for a medical condition?” Circle Yes

or

No

If Yes: “Please describe the condition”:
13. “Are you taking any prescription or over-the-counter medications?” Circle Yes or

No

If Yes: “Please identify the medication”:
14. Do you have any psychiatric conditions like depression or anxiety?
Circle Yes
or
No
If Yes: “Please describe the condition”:
15. “Have you ever been diagnosed with high or low blood pressure?” Circle Yes or

No

If Yes: “Please indicate whether it is high or low”:
Cigarette use:
16. Have you smoked tobacco cigarettes in the past year?
Circle Yes or No
If Yes: “When was the most recent occasion you smoked tobacco cigarettes?
Circle: Within the past 30 days
6 months ago

or

2 to 3 months ago

or 4 to 6 months ago or More than

If No: Go to Question 19
17. “How many cigarettes/day do you smoke?” Write in exact number and also circle
appropriate category: ________ (num of cigs)
10 or less

11-20

21-30

31 or more

18. “For how long have you smoked this number?”
yrs)
19. “Have you ever used an electronic cigarette?”

________ (months or

Circle Yes

or

No

If Yes: ask the following questions
“Do you use an electronic cigarette regularly?”
Circle Yes
or
No
If no, ask “how many times have you ever used an ECIG?” ______________
“What is your preferred e-cig brand?”

____________________
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“Do you ever use other brands of e-cig?”

____________________

“What is your preferred cartridge or e-liquid strength?”

____________________

“Do you ever use other strengths?”

____________________

“On average, how many cartridges or ml e-liquid do you vape per day? (Please indicate
liquid or cartridge)”
____________________
“For how long have you been using this amount?”

____________________

“Where do you purchase your e-cig cartridges and/or nicotine solution?”__________
Interviewer: “I am now going to ask questions about alcohol and drug use. Please remember
that you are not required to answer any question and you may stop this interview at any time.”
Alcohol use:
20. “Have you ever been treated for alcohol abuse/dependence?” Circle Yes
If Yes: “When was your treatment completed?”:
21. “Do you use (drink) alcoholic beverages?”

or

No

___________(mnth/year)
Circle Yes

or

No

If No: Skip the remainder of this section.
22. “How many alcoholic drinks (by alcohol I mean beer, wine, or liquor)
do you have on a typical day?
_______ (num of drinks)
23. “How many days out of the last 30 have you used alcohol?”_______ (num of days)
-----------------------------------------------------------------------------------------------------------Marijuana use:
24. Have you ever, in your lifetime, smoked marijuana or hashish? Circle Yes
or
No
If No: Skip the next question.
25. “How many days out of the last 30 have you smoked marijuana?”
days)

_______ (number of

------------------------------------------------------------------------------------------------------------------------------------------------------------------

Other drug use:
26. “Have you used any other illegal drugs within the past month? Circle Yes
If Yes: “Please identify which drug or drugs.”

or

No
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-----------------------------------------------------------------------------------------------------------For women only:
27. “Are you currently pregnant?”
Circle Yes
or
No
28. “Are you currently breast-feeding a child?”
29. “What was the first day of your last period?”

Circle Yes

or

No
________________

Interviewer: “Thank you for responding to these questions. I need to pass on your responses to
the principal investigator who will then determine whether or not you are eligible to participate
in a study; someone will contact you within approximately one week if you are eligible. If you
are not eligible for any of our current studies, then you will not be contacted.”
[If respondent does not have a phone, they can call us back in a few days]
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APPENDIX B
Informed Consent Form
Title. Effects of electronic cigarette dose and user experience
VCU IRB Number: HM 20000629
Investigator. Dr. Thomas Eissenberg
Sponsor. National Institutes of Health
This consent form may contain words that you do not understand. Please ask the study staff to
explain any words that you do not clearly understand. You may take home an unsigned copy of
this consent form to think about or discuss with family or friends before making your decision.
Purpose of the study. The purpose of this research study is to learn about how you use
electronic cigarettes (e-cigarettes) and what effects they produce.
Description of the study and procedures. If you agree to join the study, you will be asked
questions about your general health, smoking history, and marijuana and alcohol use. If you are
a woman you will need to provide a urine sample that will be tested immediately for pregnancy.
If you are pregnant you cannot participate in this study. Your responses will be confidential.
If the urine tests and your answers to our questions indicate that you fulfill the entry criteria, we
will ask you to participate in four, approximately 2.5-hour sessions here at the Clinical
Behavioral Pharmacology Laboratory located on VCU’s medical campus. The four sessions will
begin at approximately the same time each day, will be separated by at least 48 hours, and will
occur no more than twice per week. Before each session, we will ask you to abstain from all ecigarette and other tobacco products for at least 12 hours. We will also ask you to abstain from
all food and caffeinated beverages for 1 hour before each session. In addition, the use of any
nicotine-containing products (like the gum or patch) is prohibited. We will ask you to take a
simple breath test to make sure that you have complied with these restrictions. Our tests are not
perfect, but they are the only measures that we can accept to make certain that you have
complied with the no tobacco/no nicotine restrictions.
At the beginning of each session, a nurse will insert an IV catheter into your arm that will stay
there for the entire session. This catheter will be used to draw blood periodically (less than 1
tablespoon per sample, 10 samples each session). We use this method because participants tell us
that it is more comfortable than repeated “sticks” with a needle. During this session we will take
much less blood than the amount you would give in a single donation at a blood drive. Inserting
a catheter can be challenging for some individuals with smaller veins or veins that are harder to
see. In this laboratory we will attempt to insert a catheter no more than three times in one day
and, if all three attempts are unsuccessful, we will discontinue the session and pay you for the
time that you spent complying with study conditions before the session began ($15) and also for
the time you spent in the laboratory ($15/hour).
We will also monitor your heart rate and blood pressure and ask you to respond to several
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questionnaires to measure how you feel before and after you use an e-cigarette.
For each session, we will ask you to use an e-cigarette that we provide. The e-cigarette may
contain nicotine or no nicotine. Neither you nor the study staff will know what each e-cigarette
contains. During each session we will ask you to use the e-cigarette at two separate times. Each
time, we will ask you to take only 10 puffs, and we will tell you when to take each of these
puffs. At each of these two times we need you to remain seated in a comfortable chair while you
are using the e-cigarette.
When you use the e-cigarette, you may notice that it is connected to a computer and that there
are pieces of equipment attached to the e-cigarette. The computer and this equipment are
measuring how you are using the e-cigarette (the size and number of the puffs that you take).
Your participation in this study will help us understand how people use e-cigarettes and what
effects e-cigarettes produce. You will have an opportunity to experience all of the questionnaires
and see all of the equipment before your first session.
Risks and Discomforts: You may experience some discomfort during abstinence from ecigarettes and nicotine before the session or while using e-cigarettes during the session. Side
effects from products that contain nicotine can include sweating, lightheadedness, dizziness,
nausea, and nervousness. These effects are unlikely in individuals who use nicotine-containing
products regularly. Side effects from tobacco/nicotine abstinence can include irritability, anxiety
and restlessness, excessive hunger, difficulty concentrating, and sleep disturbance. Though these
potential side effects have not been characterized in e-cigarettes users, they are common
abstinence symptoms in cigarette smokers. Though uncomfortable, these feelings are not
medically dangerous. You may also feel some discomfort when the nurse inserts or withdraws
the needle, or when blood samples are taken. There is some risk of bruising at the catheter site,
and there is a minimal risk of infection associated with any blood draw. We try very hard to
minimize your discomfort at these times, and the use of a trained nurse and sterile, disposable
equipment enhances comfort while reducing the risk of bruising and infection. If you find any
effects or data collection procedures unacceptable, you may stop your participation at any time.
You should not donate blood 4 weeks before or 4 weeks after this study.
Benefits. You will derive no personal benefit from this study. However, your participation will
help us in the future as we try to improve our measuring equipment.
Costs of Participation. There is no cost to you for participation except for your time.
Participating in this study will take about 14 hours in the laboratory.
Payment for Participation. You will be paid for the time that you are not using tobacco prior
to each session and for your time in the laboratory: you will receive $75 after completing the first
session, $75 after completing the second session, $150 after completing the third session, and
$200 after completing the fourth session. Thus, the total amount you could earn for the entire
study is $500. If you choose to leave the study early, you will keep what you have earned up to
that point. For example, if you complete one session, you will earn $75.
In the event a session is begun but not completed (for reasons beyond your control), you will not
receive full payment for a completed session. Instead, you will receive partial payment for the
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time spent complying with study conditions before the session began ($15) and also for the time
spent in the laboratory ($15/hour).
Alternatives. This is not a therapeutic study. You have the alternative not to participate.
Confidentiality. We will not tell anyone the answers that you give us; however, information
from the study and the consent form signed by you may be looked at or copied for research or
legal purposes by the sponsor of the research, or by Virginia Commonwealth University.
Confidentiality of your records will be maintained by keeping all data in a locked file and in a
coded database. Release of this information will be withheld, consistent with the law, unless you
give permission to release this information. The information obtained in this study may be
published, but your identity will not be revealed.
Compensation for Injury. Virginia Commonwealth University and the VCU Health System
(formerly known as the Medical College of Virginia Hospitals) have no plan for providing longterm care or compensation in the event that you suffer injury as a result of your participation in
this research study. If you are injured or if you become ill as a result of your participation in this
study, contact your study nurse immediately. Your study nurse will arrange for short term
emergency care or referral if it is needed. Fees for such treatment may be billed to you or to
appropriate third party insurance. Your health insurance company may or may not pay for
treatment of injuries as a result of your participation in this study.
Pregnancy. Every effort will be made to have women enter this study on an equal basis with
men. Tobacco use may be harmful to a fetus, and pregnant women may not participate in this
study. If you suspect that you are pregnant, or if you are currently breast-feeding a baby, please
inform the investigator now and do not participate. We will conduct a urine pregnancy test
during the screening evaluation visit to ensure that pregnant women do not participate.
Voluntary Participation and Withdrawal. You do not have to participate in this study. If you
choose to participate you may stop at any time without any penalty. You may also choose not to
answer particular questions that are asked in this study. The investigators will answer any
questions that you may have. If you choose not to participate or to discontinue your
participation, this choice will in no way affect any medical care you receive now or in the future
at this institution. If during the course of the study you experience adverse effects, or if you do
not comply with the study restrictions, your participation may be stopped by Dr. Eissenberg
without your consent. Any significant new findings that develop during the course of the
research study that may affect your willingness to continue to participate will be provided to you.
Questions. You can call Dr. Eissenberg at 827-3562 for information about the research or about
research-related injury.
Participants' Rights Information. If you have questions about your rights as a research
participant, you may contact:
Office for Research Subjects Protection
Virginia Commonwealth University
Virginia Biotechnology Research Park, BioTech One
800 East Leigh Street, Suite 115, P.O. Box 980219
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Richmond, VA 23298-0219
Telephone: 804-828-0868
If you agree to join this study, please print and sign your name below. You will receive a copy
of this consent form.
Consent. I have read this consent form. I understand the information about this study. All my
questions about the study and my participation in it have been answered. I freely consent to
participate in this research study.
By signing this consent form I have not waived any of the legal rights which I otherwise would
have as a participant in a research study.
______________________________________
Participant’s Printed Name
______________________________________
Signature of Participant

__________________
Date

______________________________________
Signature of Person Performing Consent

__________________
Date

______________________________________
Witness’s Printed Name
______________________________________
Signature of Witness

__________________
Date

______________________________________
Signature of Investigator

__________________
Date
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APPENDIX C
Hughes-Hatsukami Withdrawal VAS Scale (Hughes & Hatsukami, 1986).

These phrases may or may not describe how you feel right now.
Please respond to each word of phrase
Not atwith how you feel RIGHT NOW
All
1.

Urges to use an e-cigarette

2.

Irritability/frustration/anger

3. Anxious

4 Difficulty Concentrating

5. Restlessness

6.

Hunger

7.

Impatient

8.

CRAVING an e-cigarette

9. Drowsiness

10. Depression/ feeling blue

11. Desire for Sweets

Extremely
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APPENDIX D
Direct Effects of ECIG Use Scale
These phrases may or may not describe how you feel right now.
Please respond to each word of phrase with how you feel RIGHT NOW by
drawing a vertical mark anywhere along the horizontal line.

Not at
All
1.

Was the e-cig satisfying?

2.

Was the e-cig pleasant?

3. Did the ecig taste good?

4. Did the e-cig make you dizzy?

5. Did the e cig
calm you
down?

6. Did the ecig help you
concentrate?

7. Did the ecig make you
feel more
awake?

Extremely
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8. Did the e-cig reduce your
hunger for food?

9. Did the ecig make you
sick?

10. Would you like to use another ecig RIGHT NOW?
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APPENDIX E
Acceptability Questionnaire
These phrases may or may not describe how you feel right now.
Please respond to each word of phrase with how you feel RIGHT NOW by
drawing a vertical mark anywhere along the horizontal line.

Did the ECIG/equipment that you used today:
Not at All
1.

Alter your vaping behavior?

2.

Make you less likely to want
to vape today?

3. Reduce your vaping
enjoyment
today?

4.

Affect the taste of the ECIG
that you smoked today?

5. Make vaping more difficult?

6. Increase your awareness of
how
much you vaped today?

Extremely
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APPENDIX F
Questionnaire of Smoking Urges- Brief
For each item, please indicate how you feel RIGHT NOW
I have a desire for a cigarette right now.
Strongly
disagree

Strongly
agree

Strongly
disagree

Strongly
agree

Strongly
disagree

Strongly
agree

Strongly
disagree

Strongly
agree

Strongly
disagree

Strongly
agree

Strongly
disagree

Strongly
agree

Strongly
disagree

Strongly
agree

Nothing would be better than smoking a cigarette right now.

If it were possible, I probably would smoke now.

I could control things better right now if I could smoke.

All I want right now is a cigarette

I have an urge for a cigarette.

A cigarette would taste good now.

I would do almost anything for a cigarette now.
Strongly
disagree

Strongly
agree

Strongly
disagree

Strongly
agree

Strongly
disagree

Strongly
agree

Smoking would make me less depressed.

I am going to smoke as soon as possible.
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